<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.1d3 20150301//EN" "http://jats.nlm.nih.gov/publishing/1.1d3/JATS-journalpublishing1.dtd">
<article article-type="research-article" dtd-version="1.1d3" xml:lang="en" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">PLoS ONE</journal-id>
<journal-id journal-id-type="publisher-id">plos</journal-id>
<journal-id journal-id-type="pmc">plosone</journal-id>
<journal-title-group>
<journal-title>PLOS ONE</journal-title>
</journal-title-group>
<issn pub-type="epub">1932-6203</issn>
<publisher>
<publisher-name>Public Library of Science</publisher-name>
<publisher-loc>San Francisco, CA USA</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1371/journal.pone.0191788</article-id>
<article-id pub-id-type="publisher-id">PONE-D-17-28595</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Research Article</subject>
</subj-group>
<subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Organisms</subject><subj-group><subject>Eukaryota</subject><subj-group><subject>Animals</subject><subj-group><subject>Vertebrates</subject><subj-group><subject>Amniotes</subject><subj-group><subject>Mammals</subject><subj-group><subject>Leporids</subject><subj-group><subject>Rabbits</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Research and analysis methods</subject><subj-group><subject>Experimental organism systems</subject><subj-group><subject>Animal models</subject><subj-group><subject>Rabbits</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and health sciences</subject><subj-group><subject>Diagnostic medicine</subject><subj-group><subject>Signs and symptoms</subject><subj-group><subject>Hemorrhage</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and health sciences</subject><subj-group><subject>Pathology and laboratory medicine</subject><subj-group><subject>Signs and symptoms</subject><subj-group><subject>Hemorrhage</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and health sciences</subject><subj-group><subject>Vascular medicine</subject><subj-group><subject>Hemorrhage</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Anatomy</subject><subj-group><subject>Body fluids</subject><subj-group><subject>Blood</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and health sciences</subject><subj-group><subject>Anatomy</subject><subj-group><subject>Body fluids</subject><subj-group><subject>Blood</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Physiology</subject><subj-group><subject>Body fluids</subject><subj-group><subject>Blood</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and health sciences</subject><subj-group><subject>Physiology</subject><subj-group><subject>Body fluids</subject><subj-group><subject>Blood</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and health sciences</subject><subj-group><subject>Neurology</subject><subj-group><subject>Cerebrovascular diseases</subject><subj-group><subject>Stroke</subject><subj-group><subject>Ischemic stroke</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and health sciences</subject><subj-group><subject>Vascular medicine</subject><subj-group><subject>Stroke</subject><subj-group><subject>Ischemic stroke</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Research and analysis methods</subject><subj-group><subject>Research assessment</subject><subj-group><subject>Systematic reviews</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Anatomy</subject><subj-group><subject>Cardiovascular anatomy</subject><subj-group><subject>Blood vessels</subject><subj-group><subject>Arteries</subject><subj-group><subject>Cerebral arteries</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and health sciences</subject><subj-group><subject>Anatomy</subject><subj-group><subject>Cardiovascular anatomy</subject><subj-group><subject>Blood vessels</subject><subj-group><subject>Arteries</subject><subj-group><subject>Cerebral arteries</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Anatomy</subject><subj-group><subject>Brain</subject><subj-group><subject>Cerebral hemispheres</subject><subj-group><subject>Left hemisphere</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and health sciences</subject><subj-group><subject>Anatomy</subject><subj-group><subject>Brain</subject><subj-group><subject>Cerebral hemispheres</subject><subj-group><subject>Left hemisphere</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Anatomy</subject><subj-group><subject>Brain</subject><subj-group><subject>Cerebral hemispheres</subject><subj-group><subject>Right hemisphere</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and health sciences</subject><subj-group><subject>Anatomy</subject><subj-group><subject>Brain</subject><subj-group><subject>Cerebral hemispheres</subject><subj-group><subject>Right hemisphere</subject></subj-group></subj-group></subj-group></subj-group></subj-group></article-categories>
<title-group>
<article-title>Microbubbles combined with ultrasound therapy in ischemic stroke: A systematic review of in-vivo preclinical studies</article-title>
<alt-title alt-title-type="running-head">Sonothrombolysis with microbubbles in ischemic stroke - an assessment of pre-clinical evidence</alt-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" xlink:type="simple">
<contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0002-7379-8506</contrib-id>
<name name-style="western">
<surname>Auboire</surname>
<given-names>Laurent</given-names>
</name>
<role content-type="http://credit.casrai.org/">Conceptualization</role>
<role content-type="http://credit.casrai.org/">Data curation</role>
<role content-type="http://credit.casrai.org/">Formal analysis</role>
<role content-type="http://credit.casrai.org/">Investigation</role>
<role content-type="http://credit.casrai.org/">Methodology</role>
<role content-type="http://credit.casrai.org/">Project administration</role>
<role content-type="http://credit.casrai.org/">Writing – original draft</role>
<role content-type="http://credit.casrai.org/">Writing – review &amp; editing</role>
<xref ref-type="aff" rid="aff001"><sup>1</sup></xref>
<xref ref-type="aff" rid="aff002"><sup>2</sup></xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>Sennoga</surname>
<given-names>Charles A.</given-names>
</name>
<role content-type="http://credit.casrai.org/">Data curation</role>
<role content-type="http://credit.casrai.org/">Validation</role>
<role content-type="http://credit.casrai.org/">Writing – original draft</role>
<role content-type="http://credit.casrai.org/">Writing – review &amp; editing</role>
<xref ref-type="aff" rid="aff001"><sup>1</sup></xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>Hyvelin</surname>
<given-names>Jean-Marc</given-names>
</name>
<role content-type="http://credit.casrai.org/">Writing – review &amp; editing</role>
<xref ref-type="aff" rid="aff003"><sup>3</sup></xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>Ossant</surname>
<given-names>Fréderic</given-names>
</name>
<role content-type="http://credit.casrai.org/">Writing – review &amp; editing</role>
<xref ref-type="aff" rid="aff001"><sup>1</sup></xref>
<xref ref-type="aff" rid="aff004"><sup>4</sup></xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>Escoffre</surname>
<given-names>Jean-Michel</given-names>
</name>
<role content-type="http://credit.casrai.org/">Validation</role>
<role content-type="http://credit.casrai.org/">Writing – original draft</role>
<role content-type="http://credit.casrai.org/">Writing – review &amp; editing</role>
<xref ref-type="aff" rid="aff001"><sup>1</sup></xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>Tranquart</surname>
<given-names>François</given-names>
</name>
<role content-type="http://credit.casrai.org/">Supervision</role>
<role content-type="http://credit.casrai.org/">Writing – original draft</role>
<role content-type="http://credit.casrai.org/">Writing – review &amp; editing</role>
<xref ref-type="aff" rid="aff005"><sup>5</sup></xref>
</contrib>
<contrib contrib-type="author" corresp="yes" xlink:type="simple">
<name name-style="western">
<surname>Bouakaz</surname>
<given-names>Ayache</given-names>
</name>
<role content-type="http://credit.casrai.org/">Conceptualization</role>
<role content-type="http://credit.casrai.org/">Project administration</role>
<role content-type="http://credit.casrai.org/">Supervision</role>
<role content-type="http://credit.casrai.org/">Validation</role>
<role content-type="http://credit.casrai.org/">Writing – original draft</role>
<role content-type="http://credit.casrai.org/">Writing – review &amp; editing</role>
<xref ref-type="aff" rid="aff001"><sup>1</sup></xref>
<xref ref-type="corresp" rid="cor001">*</xref>
</contrib>
</contrib-group>
<aff id="aff001"><label>1</label> <addr-line>UMR Imagerie et Cerveau, Inserm U930, Université François-Rabelais de Tours, France</addr-line></aff>
<aff id="aff002"><label>2</label> <addr-line>CHRU de Tours, Service d’échographie-Doppler, Tours, France</addr-line></aff>
<aff id="aff003"><label>3</label> <addr-line>Bracco Suisse SA, Geneva, Switzerland</addr-line></aff>
<aff id="aff004"><label>4</label> <addr-line>CHRU de Tours, CIC-IT, Tours, France</addr-line></aff>
<aff id="aff005"><label>5</label> <addr-line>Advice-US Consulting, Nernier, France</addr-line></aff>
<contrib-group>
<contrib contrib-type="editor" xlink:type="simple">
<name name-style="western">
<surname>Lapchak</surname>
<given-names>Paul A.</given-names>
</name>
<role>Editor</role>
<xref ref-type="aff" rid="edit1"/>
</contrib>
</contrib-group>
<aff id="edit1"><addr-line>Cedars-Sinai Medical Center, UNITED STATES</addr-line></aff>
<author-notes>
<fn fn-type="conflict" id="coi001">
<p>Bracco Suisse SA provided support in the form of salaries for author [JMH], Advice-US consulting provided support in the form of salaries for author [FT]. Bracco Suisse SA and Advice-US consulting did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific roles of these authors are articulated in the ‘author contributions’ section. This does not alter our adherence to PLOS ONE policies on sharing data and materials.</p>
</fn>
<corresp id="cor001">* E-mail: <email xlink:type="simple">Ayache.bouakaz@univ-tours.fr</email></corresp>
</author-notes>
<pub-date pub-type="epub">
<day>8</day>
<month>2</month>
<year>2018</year>
</pub-date>
<pub-date pub-type="collection">
<year>2018</year>
</pub-date>
<volume>13</volume>
<issue>2</issue>
<elocation-id>e0191788</elocation-id>
<history>
<date date-type="received">
<day>1</day>
<month>8</month>
<year>2017</year>
</date>
<date date-type="accepted">
<day>29</day>
<month>12</month>
<year>2017</year>
</date>
</history>
<permissions>
<copyright-year>2018</copyright-year>
<copyright-holder>Auboire et al</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/" xlink:type="simple">
<license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/" xlink:type="simple">Creative Commons Attribution License</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p>
</license>
</permissions>
<self-uri content-type="pdf" xlink:href="info:doi/10.1371/journal.pone.0191788"/>
<abstract>
<sec id="sec001">
<title>Background</title>
<p>Microbubbles (MBs) combined with ultrasound sonothrombolysis (STL) appears to be an alternative therapeutic strategy for acute ischemic stroke (IS), but clinical results remain controversial.</p>
</sec>
<sec id="sec002">
<title>Objective</title>
<p>The aim of this systematic review is to identify the parameters tested; to assess evidence on the safety and efficacy on preclinical data on STL; and to assess the validity and publication bias.</p>
</sec>
<sec id="sec003">
<title>Methods</title>
<p>Pubmed<sup>®</sup> and Web of Science<sup>TM</sup> databases were systematically searched from January 1995 to April 2017 in French and English. We included studies evaluating STL on animal stroke model. This systematic review was conducted in accordance with the PRISMA guidelines. Data were extracted following a pre-defined schedule by two of the authors. The CAMARADES criteria were used for quality assessment. A narrative synthesis was conducted.</p>
</sec>
<sec id="sec004">
<title>Results</title>
<p>Sixteen studies met the inclusion criteria. The result showed that ultrasound parameters and types of MBs were heterogeneous among studies. Numerous positive outcomes on efficacy were found, but only four studies demonstrated superiority of STL versus recombinant tissue-type plasminogen activator on clinical criteria. Data available on safety are limited.</p>
</sec>
<sec id="sec005">
<title>Limitations</title>
<p>Quality assessment of the studies reviewed revealed a number of biases.</p>
</sec>
<sec id="sec006">
<title>Conclusion</title>
<p>Further in vivo studies are needed to demonstrate a better efficacy and safety of STL compared to currently approved therapeutic options.</p>
</sec>
<sec id="sec007">
<title>Systematic review registration</title>
<p><ext-link ext-link-type="uri" xlink:href="http://syrf.org.uk/protocols/" xlink:type="simple">http://syrf.org.uk/protocols/</ext-link></p>
</sec>
</abstract>
<funding-group>
<award-group id="award001">
<funding-source>
<institution>INSERM</institution>
</funding-source>
<principal-award-recipient>
<name name-style="western">
<surname>Bouakaz</surname>
<given-names>Ayache</given-names>
</name>
</principal-award-recipient>
</award-group>
<award-group id="award002">
<funding-source>
<institution>Bracco suisse SA</institution>
</funding-source>
<principal-award-recipient>
<name name-style="western">
<surname>Hyvelin</surname>
<given-names>Jean-Marc</given-names>
</name>
</principal-award-recipient>
</award-group>
<award-group id="award003">
<funding-source>
<institution>Advice-US consulting</institution>
</funding-source>
<principal-award-recipient>
<name name-style="western">
<surname>Tranquart</surname>
<given-names>François</given-names>
</name>
</principal-award-recipient>
</award-group>
<funding-statement>This work was funded by INSERM. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. This does not alter our adherence to PLOS ONE policies on sharing data and materials.</funding-statement>
</funding-group>
<counts>
<fig-count count="1"/>
<table-count count="7"/>
<page-count count="19"/>
</counts>
<custom-meta-group>
<custom-meta id="data-availability">
<meta-name>Data Availability</meta-name>
<meta-value>All relevant data are within the paper and its Supporting Information files. The protocol is available at <ext-link ext-link-type="uri" xlink:href="http://syrf.org.uk/protocols/" xlink:type="simple">http://syrf.org.uk/protocols/</ext-link>.</meta-value>
</custom-meta>
</custom-meta-group>
</article-meta>
</front>
<body>
<sec id="sec008" sec-type="intro">
<title>Introduction</title>
<p>Ischemic stroke (IS), described as death of neuronal cells due to arrest of regional cerebral blood flow by intra-arterial thrombi, is the second most common cause of death and the first leading cause of disability worldwide [<xref ref-type="bibr" rid="pone.0191788.ref001">1</xref>]. Although intravenous (IV) administration of recombinant tissue-type plasminogen activator (rtPA), the only thrombolytic agent approved for the reperfusion of occluded arteries, shows improved outcomes in terms of mortality and disability in IS patients, its use is characterized by increased incidences of hemorrhage [<xref ref-type="bibr" rid="pone.0191788.ref002">2</xref>]. Patients ineligible for rtPA or failing to recanalize with rtPA are now treatable using thrombectomy. However, thrombectomy is presently used only at comprehensive stroke centers and limited to an artery with a diameter &gt; 2 mm [<xref ref-type="bibr" rid="pone.0191788.ref003">3</xref>, <xref ref-type="bibr" rid="pone.0191788.ref004">4</xref>]. Use of other thrombolytic drugs (e.g., tenecteplase) were previously trialled, but showed no beneficial improvements in treatment outcomes when compared with rtPA [<xref ref-type="bibr" rid="pone.0191788.ref005">5</xref>].</p>
<p>Sonothrombolysis (STL), involving the use of microbubbles (MBs) combined with transcranial ultrasound (US) to potentiate clot dissolution with or without administration of rtPA, is under clinical evaluation as a method for the recanalization of occluded cerebral arteries [<xref ref-type="bibr" rid="pone.0191788.ref006">6</xref>–<xref ref-type="bibr" rid="pone.0191788.ref008">8</xref>]. A meta-analysis of clinical STL shows no beneficial treatment outcome in terms of mortality and disability at 3 months versus approved treatment (rtPA). Patients also experience a higher rate of cerebral hemorrhage [<xref ref-type="bibr" rid="pone.0191788.ref009">9</xref>]. Another meta-analysis of randomized controlled trials and case-control studies concluded that sonothrombolysis with microbubbles is a safe and effective treatment in ischemic stroke [<xref ref-type="bibr" rid="pone.0191788.ref010">10</xref>]. A more recent clinical trial, NOR-SASS (Norwegian Sonothrombolysis in Acute Stroke Study), which was prematurely interrupted (lack of funding), concluded that the use of STL is safe as a thrombolytic therapy and with no significant adverse effects [<xref ref-type="bibr" rid="pone.0191788.ref008">8</xref>].</p>
<p>Twenty years after the demonstration by Tachibana et al. that STL with microbubbles has a thrombolytic effect, numerous studies have been performed in Vivo [<xref ref-type="bibr" rid="pone.0191788.ref011">11</xref>]. If comprehensive review on the subject are available [<xref ref-type="bibr" rid="pone.0191788.ref012">12</xref>–<xref ref-type="bibr" rid="pone.0191788.ref015">15</xref>], no systematic review on in-vivo studies has been performed yet. Such review is required to summarize the evidence accumulated, to provide transparency on the quality of these studies and help to design new studies, which can ease clinical translation. This systematic review will focus on the association of microbubbles and ultrasound for sonothrombolysis. Other approaches such as histotripsy or sonothrombolysis without microbubbles will not be included in this review to maintain a homogeneity in the parameters tested.</p>
<p>The purpose of this systematic review is (i) to identify the parameters tested and their results, (ii) to assess evidence on the safety and efficacy from preclinical data on STL, and (iii) to assess the validity of the reviewed study and identify publication bias.</p>
</sec>
<sec id="sec009" sec-type="materials|methods">
<title>Methods</title>
<p>Pubmed<sup>®</sup> and Web of Science<sup>TM</sup> electronic databases were screened by two of the authors (LA, CAS) using pre-defined search terms (January 1995–April 2017) for preclinical in vivo reports employing STL or STL combined with rtPA (rtPA-STL) in IS. The search terms ((stroke [MeSH Terms] OR fibrinolytic drugs [MeSh Terms] OR thrombolytic OR thrombolytic agents [MeSH Terms] OR thrombolytic drugs [MeSH Terms]) AND (microbubbles [MeSH Terms] OR microspheres [MeSH Terms]) AND ("French" [language] OR "English" [language])) OR “sonothrombolysis” were used on the Pubmed<sup>®</sup> database. The search terms (“thrombolytic therapy OR stroke”) AND (“microbubbles OR microspheres”) OR “sonothrombolysis”, (“ultrasound contrast agents AND stroke”) were used on the Web of Science<sup>TM</sup> database. The search term “ultrasound AND thrombolysis” was used on both databases. The full electronic search strategy for the two databases are available in <xref ref-type="supplementary-material" rid="pone.0191788.s002">S1 File</xref>. The inclusion and exclusion criteria are summarized in <xref ref-type="table" rid="pone.0191788.t001">Table 1</xref>. Data were extracted by two of the authors (LA, CAS) following a pre-defined schedule including: species, stroke model, type of clot, duration of clotting, duration of ischemia, ultrasound parameters (frequency, duty cycle, duration of insonation, position of the ultrasound transducer, acoustic power, and peak negative pressure), microbubbles characteristics (type, route of administration, thrombolytic drug associated, volume of injection, and concentration of microbubbles per kilogram), significant outcomes, and quality evaluation. The Collaborative Approach to Meta-Analysis and Review of Animal Data from Experimental Studies (CAMARADES) was used to assess the quality and risk of bias of the studies included [<xref ref-type="bibr" rid="pone.0191788.ref016">16</xref>]. This systematic review was written in accordance with the PRISMA guidelines [<xref ref-type="bibr" rid="pone.0191788.ref017">17</xref>]. The protocol was registered on the CAMARADES-NC3Rs Preclinical Systematic Review &amp; Meta-analysis Facility (SyRF) and is available online (<ext-link ext-link-type="uri" xlink:href="https://drive.google.com/file/d/0B7Z0eAxKc8ApWi1HY3lvNU1pU2M/view" xlink:type="simple">https://drive.google.com/file/d/0B7Z0eAxKc8ApWi1HY3lvNU1pU2M/view</ext-link>).</p>
<table-wrap id="pone.0191788.t001" position="float">
<object-id pub-id-type="doi">10.1371/journal.pone.0191788.t001</object-id>
<label>Table 1</label> <caption><title>Inclusion and exclusion criteria used to select studies.</title></caption>
<alternatives>
<graphic id="pone.0191788.t001g" mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pone.0191788.t001" xlink:type="simple"/>
<table>
<colgroup>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
</colgroup>
<thead>
<tr>
<th align="center">Inclusion Criteria</th>
<th align="center">Exclusion Criteria</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left">Concerning Stroke</td>
<td align="left">Sonothrombolysis without microbubbles</td>
</tr>
<tr>
<td align="left">Involving microbubbles</td>
<td align="left">Review papers</td>
</tr>
<tr>
<td align="left">On animals</td>
<td align="left">Comments, Letters</td>
</tr>
<tr>
<td align="left">French or English</td>
<td align="justify">Studies concerning other arteries not directly supplying the brain<break/>(List of arteries included: cerebral artery, carotid artery, vertebral artery, <italic>rete mirabele</italic> and pharyngeal artery in pig)</td>
</tr>
<tr>
<td align="center">With Thrombolytic drugs or not</td>
<td align="left">Neuro-protective study without thrombolysis</td>
</tr>
<tr>
<td align="center"/>
<td align="left">Studies involving humans</td>
</tr>
<tr>
<td align="center"/>
<td align="left"><italic>In vitro</italic> studies</td>
</tr>
</tbody>
</table>
</alternatives>
</table-wrap>
</sec>
<sec id="sec010" sec-type="results">
<title>Results</title>
<sec id="sec011">
<title>Studies selected</title>
<p>Sixteen studies met the inclusion criteria (<xref ref-type="table" rid="pone.0191788.t002">Table 2</xref>). The selection schedule used is illustrated in <xref ref-type="fig" rid="pone.0191788.g001">Fig 1</xref>.</p>
<fig id="pone.0191788.g001" position="float">
<object-id pub-id-type="doi">10.1371/journal.pone.0191788.g001</object-id>
<label>Fig 1</label>
<caption>
<title>PRISMA 2009 flow diagram.</title>
<p>Extracting schedule of the studies.</p>
</caption>
<graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pone.0191788.g001" xlink:type="simple"/>
</fig>
<table-wrap id="pone.0191788.t002" position="float">
<object-id pub-id-type="doi">10.1371/journal.pone.0191788.t002</object-id>
<label>Table 2</label> <caption><title>General description of studies that fulfilled the inclusion/exclusion criteria.</title></caption>
<alternatives>
<graphic id="pone.0191788.t002g" mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pone.0191788.t002" xlink:type="simple"/>
<table>
<colgroup>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
</colgroup>
<tbody>
<tr>
<td align="left"><bold>5 studies focused only on STL treatment efficacy</bold></td>
<td align="left">1. Moumouh et al. (2009), with microbubbles (SonoVue<sup>®</sup>) alone<break/>2. Culp et al. (2003), with lipid shelled microbubbles alone<break/>3. Wang et al. (2008), with targeted microbubbles (eptifibatide) alone<break/>4. Alonso et al. (2009), with targeted microbubbles (abciximab) alone<break/>5. Culp et al. (2004), with targeted microbubbles (eptifibatide) alone</td>
</tr>
<tr>
<td align="left"><bold>4 studies focused on safety and efficacy of STL</bold></td>
<td align="left">1. Culp et al. (2011), with targeted or non-targeted microbubbles (Definity<sup>®</sup>, or custom 3 μm microbubbles), or targeted microbubbles (eptifibatide) alone<break/>2. Liu et al. (2012), with microbubbles (SonoVue<sup>®</sup>) with Urokinase<break/>3. Ren et al. (2012), with targeted microbubbles (eptifibafide) alone<break/>4. Gao et al. (2014) with microbubbles (Definity<sup>®</sup>) alone, with the objective of determining the type and level of cavitation required to dissolve thrombi and improve cerebral blood flow</td>
</tr>
<tr>
<td align="left"><bold>2 studies focused on rtPA-STL treatment efficacy</bold></td>
<td align="left">1. Tomkins et al. (2015) with lipid shelled microbubbles (BR-38<sup>®</sup>) and rtPA on a new <italic>in-vivo</italic> model using platelet rich plasma clot<break/>2. Ren et al. (2015), tested the efficacy of rtPA-STL for thrombolysis.</td>
</tr>
<tr>
<td align="left"><bold>5 Studies focused on efficacy and safety of rtPA-STL</bold></td>
<td align="left">1. Brown et al. (2011), with Definity<sup>®</sup> or albumin/dextrose microbubbles and low dose of rtPA, addressed the possibility of reducing the dose of rtPA and decreasing the rate of intracerebral hemorrhages<break/>2. Flores et al. (2013), with microbubbles (Definity<sup>®</sup>) alone and microbubbles with rtPA<break/>3. Lu et al. (2016), attempted to determine whether STL or rtPA-STL could dissolve platelet rich or erythrocyte rich microthrombi.<break/>4. Schleicher et al. (2016) and Nedelmann et al. (2010) tested the ability of STL or rtPA-STL to improve microvascular patency after a transient vascular occlusion.</td>
</tr>
</tbody>
</table>
</alternatives>
</table-wrap>
</sec>
<sec id="sec012">
<title>Animal models and clots</title>
<p>Thrombi (0.1 mL–1 mL) were delivered into the ascending pharyngeal artery and rete mirabile using femoral catheterization in a swine model [<xref ref-type="bibr" rid="pone.0191788.ref018">18</xref>–<xref ref-type="bibr" rid="pone.0191788.ref020">20</xref>] and arterial occlusions assessed using angiography [<xref ref-type="bibr" rid="pone.0191788.ref018">18</xref>, <xref ref-type="bibr" rid="pone.0191788.ref019">19</xref>] or MRI [<xref ref-type="bibr" rid="pone.0191788.ref020">20</xref>]. Gao et al. [<xref ref-type="bibr" rid="pone.0191788.ref020">20</xref>] achieved bilateral arterial occlusions, because the right and the left ascending pharyngeal arteries supply the rete mirabile. Acute arterial occlusions, induced by blocking the right middle cerebral artery with autologous blood clots delivered by femoral catheterization, were used in a rabbit model [<xref ref-type="bibr" rid="pone.0191788.ref021">21</xref>–<xref ref-type="bibr" rid="pone.0191788.ref026">26</xref>]. Finally, five studies used a rat model of stroke with varying modifications [<xref ref-type="bibr" rid="pone.0191788.ref027">27</xref>–<xref ref-type="bibr" rid="pone.0191788.ref031">31</xref>]. Alonso et al. [<xref ref-type="bibr" rid="pone.0191788.ref027">27</xref>] injected 4 mm long human blood clots through the external carotid artery (ECA) and delivered them into a pre-ligated common carotid artery (CCA). Moumouh et al. [<xref ref-type="bibr" rid="pone.0191788.ref029">29</xref>] injected 500 μm of autologous blood clots directly into the CCA. Tomkins et al. [<xref ref-type="bibr" rid="pone.0191788.ref031">31</xref>] administered 30 mm plasma-rich clots into the internal carotid artery via the ECA and assessed vascular occlusion using laser Doppler velocimetry. Ren et al. [<xref ref-type="bibr" rid="pone.0191788.ref030">30</xref>] introduced 0.6 mm × 0.08 cm autologous clots into the left CCA. Lu et al. [<xref ref-type="bibr" rid="pone.0191788.ref028">28</xref>] injected white or red micro-thrombi into a distally ligated ECA after clamping the CCA. The clamp was subsequently removed and microthrombi were liberated into the cerebral vasculature. Nedelmann et al. and Schleicher et al. [<xref ref-type="bibr" rid="pone.0191788.ref032">32</xref>, <xref ref-type="bibr" rid="pone.0191788.ref033">33</xref>] induced a transient vascular occlusion by introducing a filament through the carotid artery in the middle cerebral artery. <xref ref-type="table" rid="pone.0191788.t003">Table 3</xref> summarizes the clot compositions, clotting time prior to injection, duration following in vivo vessel occlusion, and initiation of thrombolytic treatment employed.</p>
<table-wrap id="pone.0191788.t003" position="float">
<object-id pub-id-type="doi">10.1371/journal.pone.0191788.t003</object-id>
<label>Table 3</label> <caption><title>Summary of compositions of various clots, clotting time before injection, and time between injection and the start of treatment.</title></caption>
<alternatives>
<graphic id="pone.0191788.t003g" mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pone.0191788.t003" xlink:type="simple"/>
<table>
<colgroup>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
</colgroup>
<thead>
<tr>
<th align="center" style="background-color:#FFFFFF">References</th>
<th align="center" style="background-color:#FFFFFF">Species</th>
<th align="justify" style="background-color:#FFFFFF">Clot type</th>
<th align="center" style="background-color:#FFFFFF">Clotting time before injection (min)</th>
<th align="center" style="background-color:#FFFFFF">Time between injection of blood clot and the start of treatment (min)</th>
</tr>
</thead>
<tbody>
<tr>
<td align="justify" style="background-color:#FFFFFF"><bold>Culp et al. (2003)</bold></td>
<td align="center" style="background-color:#FFFFFF">Swine</td>
<td align="justify" style="background-color:#FFFFFF">Autologous whole blood</td>
<td align="center" style="background-color:#FFFFFF">217</td>
<td align="center" style="background-color:#FFFFFF">Immediately</td>
</tr>
<tr>
<td align="justify" style="background-color:#FFFFFF"><bold>Culp et al. (2004)</bold></td>
<td align="center" style="background-color:#FFFFFF">Swine</td>
<td align="justify" style="background-color:#FFFFFF">Autologous whole blood</td>
<td align="center" style="background-color:#FFFFFF">276</td>
<td align="center" style="background-color:#FFFFFF">Immediately</td>
</tr>
<tr>
<td align="justify" style="background-color:#FFFFFF"><bold>Gao et al. (2014)</bold></td>
<td align="center" style="background-color:#FFFFFF">Swine</td>
<td align="justify" style="background-color:#FFFFFF">Autologous whole blood</td>
<td align="center" style="background-color:#FFFFFF">NA</td>
<td align="center" style="background-color:#FFFFFF">15</td>
</tr>
<tr>
<td align="justify" style="background-color:#FFFFFF"><bold>Alonso et al. (2009)</bold></td>
<td align="center" style="background-color:#FFFFFF">Rat</td>
<td align="justify" style="background-color:#FFFFFF">Heterologous whole blood (human)</td>
<td align="center" style="background-color:#FFFFFF">120</td>
<td align="center" style="background-color:#FFFFFF">Immediately</td>
</tr>
<tr>
<td align="justify" style="background-color:#FFFFFF"><bold>Moumouh et al. (2010)</bold></td>
<td align="center" style="background-color:#FFFFFF">Rat</td>
<td align="justify" style="background-color:#FFFFFF">Autologous whole blood</td>
<td align="center" style="background-color:#FFFFFF">30</td>
<td align="center" style="background-color:#FFFFFF">240</td>
</tr>
<tr>
<td align="justify" style="background-color:#FFFFFF"><bold>Tomkins et al. (2015)</bold></td>
<td align="center" style="background-color:#FFFFFF">Rat</td>
<td align="justify" style="background-color:#FFFFFF">Autologous platelet rich clot</td>
<td align="center" style="background-color:#FFFFFF">Approx. 24H</td>
<td align="center" style="background-color:#FFFFFF">60</td>
</tr>
<tr>
<td align="justify" style="background-color:#FFFFFF"><bold>Wang et al. (2008)</bold></td>
<td align="center" style="background-color:#FFFFFF">Rabbit</td>
<td align="justify" style="background-color:#FFFFFF">Autologous whole blood</td>
<td align="center" style="background-color:#FFFFFF">226</td>
<td align="center" style="background-color:#FFFFFF">30</td>
</tr>
<tr>
<td align="justify" style="background-color:#FFFFFF"><bold>Culp et al. (2011)</bold></td>
<td align="center" style="background-color:#FFFFFF">Rabbit</td>
<td align="justify" style="background-color:#FFFFFF">Autologous whole blood</td>
<td align="center" style="background-color:#FFFFFF">4320</td>
<td align="center" style="background-color:#FFFFFF">60</td>
</tr>
<tr>
<td align="justify" style="background-color:#FFFFFF"><bold>Brown et al. (2011)</bold></td>
<td align="center" style="background-color:#FFFFFF">Rabbit</td>
<td align="justify" style="background-color:#FFFFFF">heterologous whole blood (human)</td>
<td align="center" style="background-color:#FFFFFF">180 à 300</td>
<td align="center" style="background-color:#FFFFFF">Immediately</td>
</tr>
<tr>
<td align="justify" style="background-color:#FFFFFF"><bold>Flores et al. (2011)</bold></td>
<td align="center" style="background-color:#FFFFFF">Rabbit</td>
<td align="justify" style="background-color:#FFFFFF">Heterologous whole blood (human)</td>
<td align="center" style="background-color:#FFFFFF">180</td>
<td align="center" style="background-color:#FFFFFF">Immediately</td>
</tr>
<tr>
<td align="justify" style="background-color:#FFFFFF"><bold>Ren et al. (2012)</bold></td>
<td align="center" style="background-color:#FFFFFF">Rabbit</td>
<td align="justify" style="background-color:#FFFFFF">Autologous whole blood</td>
<td align="center" style="background-color:#FFFFFF">120 à 360</td>
<td align="center" style="background-color:#FFFFFF">360</td>
</tr>
<tr>
<td align="justify" style="background-color:#FFFFFF"><bold>Liu et al. (2012)</bold></td>
<td align="center" style="background-color:#FFFFFF">Rabbit</td>
<td align="justify" style="background-color:#FFFFFF">Autologous whole blood</td>
<td align="center" style="background-color:#FFFFFF">30</td>
<td align="center" style="background-color:#FFFFFF">30</td>
</tr>
<tr>
<td align="justify" style="background-color:#FFFFFF"><bold>Ren et al. (2015)</bold></td>
<td align="center" style="background-color:#FFFFFF">Rat</td>
<td align="justify" style="background-color:#FFFFFF">Autologous whole blood</td>
<td align="center" style="background-color:#FFFFFF">180</td>
<td align="center" style="background-color:#FFFFFF">NA</td>
</tr>
<tr>
<td align="justify" style="background-color:#FFFFFF"><bold>Lu et al. (2016)</bold></td>
<td align="center" style="background-color:#FFFFFF">Rat</td>
<td align="justify" style="background-color:#FFFFFF">Autologous platelet and erythrocyte rich thrombi</td>
<td align="center" style="background-color:#FFFFFF">205</td>
<td align="center" style="background-color:#FFFFFF">5</td>
</tr>
<tr>
<td align="justify" style="background-color:#FFFFFF"><bold>Nedelmann et al. (2010)</bold></td>
<td align="center" style="background-color:#FFFFFF">Rat</td>
<td align="justify" style="background-color:#FFFFFF">Filament occlusion–microvascular impairment</td>
<td align="center" style="background-color:#FFFFFF">NA</td>
<td align="center" style="background-color:#FFFFFF">100</td>
</tr>
<tr>
<td align="justify" style="background-color:#FFFFFF"><bold>Schleicher et al. (2016)</bold></td>
<td align="center" style="background-color:#FFFFFF">Rat</td>
<td align="justify" style="background-color:#FFFFFF">Filament occlusion–microvascular impairment</td>
<td align="center" style="background-color:#FFFFFF">NA</td>
<td align="center" style="background-color:#FFFFFF">100</td>
</tr>
</tbody>
</table>
</alternatives>
</table-wrap>
</sec>
<sec id="sec013">
<title>Sonothrombolysis</title>
<p>Tables <xref ref-type="table" rid="pone.0191788.t004">4</xref> and <xref ref-type="table" rid="pone.0191788.t005">5</xref> summarize the MB type (targeting or non-targeting to receptors expressed on thrombi including the GP2B/3A: glycoprotein 2B/3A is an integrin expressed on platelets which will bind fibrinogen during platelet activation leading to an aggregation of them as they may connect to the same fibrinogen molecule), concentration, route of administration, presence or absence of thrombolytic drugs, and US parameters (e.g., frequency, duty cycle, acoustic pressure, and exposure time) employed for the reviewed STL studies.</p>
<table-wrap id="pone.0191788.t004" position="float">
<object-id pub-id-type="doi">10.1371/journal.pone.0191788.t004</object-id>
<label>Table 4</label> <caption><title>Summary of the type of microbubbles used including their dosage, administration route, protocols of injection by type of microbubbles (MBs/TMBs), and combination with thrombolytic drugs.</title></caption>
<alternatives>
<graphic id="pone.0191788.t004g" mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pone.0191788.t004" xlink:type="simple"/>
<table>
<colgroup>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
</colgroup>
<thead>
<tr>
<th align="left"/>
<th align="left" colspan="3">MB</th>
<th align="left" colspan="5">TMB</th>
<th align="left" colspan="8">MB or TMB associated with thrombolytic drugs</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left"><bold>References</bold></td>
<td align="left">Culp et al. (2003)</td>
<td align="left">Moumouh et al. (2010)</td>
<td align="left">Gao et al. (2014)</td>
<td align="left">Culp et al. (2004)</td>
<td align="left">Wang et al. (2008)</td>
<td align="left">Alonso et al. (2009)</td>
<td align="left">Culp et al. (2011)</td>
<td align="left">Ren et al. (2012)</td>
<td align="left">Nedelmann et al. (2010)</td>
<td align="left">Brown et al. (2011)</td>
<td align="left">Flores et al. (2011)</td>
<td align="left">Liu et al. (2012)</td>
<td align="left">Tomkins et al. (2015)</td>
<td align="left">Ren et al. (2015)</td>
<td align="left">Schleicher et al. (2016)</td>
<td align="left">Lu et al. (2016)</td>
</tr>
<tr>
<td align="left"><bold>Animal model</bold></td>
<td align="left">Autologous clot in a swine model</td>
<td align="left">Autologous clot in a rat model</td>
<td align="left">Autologous clot in a swine model</td>
<td align="left">Autologous clot in a swine model</td>
<td align="left">Autologous clot in a rabbit model</td>
<td align="left">Human clot in a rat model</td>
<td align="left">Autologous clot in a rabbit model</td>
<td align="left">Autologous clot in a rabbit model</td>
<td align="left">Filament occlusion in a rat<break/>microvascular impairment</td>
<td align="left">Human clot in a rabbit model</td>
<td align="left">Human clot in a rabbit model</td>
<td align="left">Autologous clot in a rabbit model</td>
<td align="left">Autologous white clot in a rat model</td>
<td align="left">Autologous clot in a rat model</td>
<td align="left">Filament occlusion in a rat model<break/>microvascular impairment</td>
<td align="left">Autologous red and white clot in a rat model</td>
</tr>
<tr>
<td align="left"><bold>Microbubbles type</bold></td>
<td align="left">Optison®</td>
<td align="left">Definity®</td>
<td align="left">Definity®</td>
<td align="left">Decafluorobutane targeted microbubbles GP2B3A, eptifibatide</td>
<td align="left">Targeted Microbubbles GP2B/3A, SF6 gas</td>
<td align="left">Targeted Microbubbles GP2B/3A abciximab</td>
<td align="left">Definity® or 3micronMB, 3microMB targeted on GP2B3A</td>
<td align="left">Targeted Microbubbles GP2B/3A</td>
<td align="left">Sonovue®</td>
<td align="left">Definity®</td>
<td align="left">Definity®</td>
<td align="left">SonoVue®</td>
<td align="left">BR38®</td>
<td align="left">Sonovue®</td>
<td align="left">BR38® or Sonovue®</td>
<td align="left">Lipid shelled perfluoropropane microbubbles</td>
</tr>
<tr>
<td align="left"><bold>Route of administration</bold></td>
<td align="left">IA</td>
<td align="left">IV</td>
<td align="left">IV</td>
<td align="left">IV</td>
<td align="left">IV or IA</td>
<td align="left">IV</td>
<td align="left">IV</td>
<td align="left">IA (intra-arterial catheter) or IV</td>
<td align="left">IV</td>
<td align="left">IV</td>
<td align="left">IV</td>
<td align="left">IV</td>
<td align="left">IV</td>
<td align="left">IV</td>
<td align="left">IV</td>
<td align="left">IV</td>
</tr>
<tr>
<td align="left"><bold>Type and dose of thrombolytic drugs</bold></td>
<td align="left">None</td>
<td align="left">None</td>
<td align="left">None</td>
<td align="left">None</td>
<td align="left">None</td>
<td align="left">None</td>
<td align="left">None</td>
<td align="left">None</td>
<td align="left">rtPA, 10 mg/kg</td>
<td align="left">rtPA, 0.1 to 0.9 mg/kg</td>
<td align="left">rtPA, 0.9mg/kg</td>
<td align="left">Urokinase, 20000 UI/ kg</td>
<td align="left">rtPA, 10 mg/kg</td>
<td align="left">rtPA, dosage not precised</td>
<td align="left">rtPA, 10 mg/kg</td>
<td align="left">rtPA, 5 or 10mg/kg</td>
</tr>
<tr>
<td align="left"><bold>Type of injection</bold></td>
<td align="left">Bolus</td>
<td align="left">Bolus</td>
<td align="left">Infusion</td>
<td align="left">Infusion</td>
<td align="left">Bolus</td>
<td align="left">Infusion</td>
<td align="left">Bolus</td>
<td align="left">Bolus</td>
<td align="left">4 Bolus</td>
<td align="left">Bolus</td>
<td align="left">Bolus</td>
<td align="left">Bolus of MB, Infusion of urokinase</td>
<td align="left">Bolus of MB, Bolus+infusion of RtPA</td>
<td align="left">Infusion</td>
<td align="left">4 Bolus</td>
<td align="left">Infusion</td>
</tr>
<tr>
<td align="left"><bold>Volume</bold></td>
<td align="left">4.5mL (1mL + 0.5 mL every 3 min)</td>
<td align="left">0.6mL (0.2mL every 10 min)</td>
<td align="left">90mL</td>
<td align="left">15 mL</td>
<td align="left">5mL</td>
<td align="left">5mL (0.2mL/min)</td>
<td align="left">6mL</td>
<td align="left">5mL (1mL x 5)</td>
<td align="left">0.4mL<break/>(0.1mLx4)</td>
<td align="left">6 mL</td>
<td align="left">6mL</td>
<td align="left">2mL</td>
<td align="left">0.4 mL (0.1mL every 15 min)</td>
<td align="left">1mL</td>
<td align="left">0.4mL<break/>(0.1x4)</td>
<td align="left">0.24mL</td>
</tr>
<tr>
<td align="left"><bold>Concentration of Microbubbles (MB/kg), average weight of animals</bold></td>
<td align="left">0.75–1.2x10^8MB/kg (30kg)</td>
<td align="left">1.92x10^9MB/kg (240-280g)</td>
<td align="left">Not available (33.9kg)</td>
<td align="justify">4.8x10^9MB/Kg<break/>(30kg)</td>
<td align="left">5.5x10^8MB/kg (3kg)</td>
<td align="left">4.48x10^10 MB/kg <break/>(446g)</td>
<td align="left">Definity® MB:<break/>1.92x10^9MB/kg<break/>For Albumin MB alone or tagged:<break/>9.61x10<sup>9</sup> MB/Kg (5.2kg)</td>
<td align="left">3.3x10^8MB/kg</td>
<td align="left">9x10^6MB/Kg<break/>(311g)</td>
<td align="left">1.92x10^9MB/kg<break/>(5.2kg)</td>
<td align="left">1.92x10^9MB/kg<break/>(5.2kg)</td>
<td align="left">0.6–3.2x10^8MB/kg<break/>(3.1kg)</td>
<td align="left">4x10^8MB/mL<break/>13.3x10^8MB/kg<break/>(300g)</td>
<td align="left">1.7–8.6x10^7MB/Kg (530-620g)</td>
<td align="left">9x10^6MB/kg (350g) for Sonovue®, 1.8x10^4MB/kg for BR38® (for full dose)</td>
<td align="left">Not available</td>
</tr>
</tbody>
</table>
</alternatives>
</table-wrap>
<table-wrap id="pone.0191788.t005" position="float">
<object-id pub-id-type="doi">10.1371/journal.pone.0191788.t005</object-id>
<label>Table 5</label> <caption><title>Summary of the US parameters utilized in the different studies.</title></caption>
<alternatives>
<graphic id="pone.0191788.t005g" mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pone.0191788.t005" xlink:type="simple"/>
<table>
<colgroup>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
</colgroup>
<thead>
<tr>
<th align="justify" style="background-color:#FFFFFF">References</th>
<th align="center" style="background-color:#FFFFFF">Culp et al. (2003)</th>
<th align="center" style="background-color:#FFFFFF">Culp et al. (2004)</th>
<th align="center" style="background-color:#FFFFFF">Wang et al. (2008)</th>
<th align="center" style="background-color:#FFFFFF">Alonso et al. (2009)</th>
<th align="center" style="background-color:#FFFFFF">Moumouh et al. (2010)</th>
<th align="center" style="background-color:#FFFFFF">Nedelmann et al. (2010)</th>
<th align="center" style="background-color:#FFFFFF">Culp et al. (2011)</th>
<th align="center" style="background-color:#FFFFFF">Brown et al. (2011)</th>
<th align="center" style="background-color:#FFFFFF">Flores et al. (2011)</th>
<th align="center" style="background-color:#FFFFFF">Ren et al. (2012)</th>
<th align="center" style="background-color:#FFFFFF">Liu et al. (2012)</th>
<th align="center" style="background-color:#FFFFFF">Gao et al. (2014)</th>
<th align="center" style="background-color:#FFFFFF">Tomkins et al. (2015)</th>
<th align="center" style="background-color:#FFFFFF">Ren et al. (2015)</th>
<th align="center" style="background-color:#FFFFFF">Lu et al. (2016)</th>
<th align="center" style="background-color:#FFFFFF">Schleicher et al. (2016)</th>
</tr>
</thead>
<tbody>
<tr>
<td align="justify" style="background-color:#FFFFFF"><bold>Animal model</bold></td>
<td align="center" style="background-color:#FFFFFF">Autologous clot in a swine model</td>
<td align="center" style="background-color:#FFFFFF">Autologous clot in a swine model</td>
<td align="center" style="background-color:#FFFFFF">Autologous clot in a rabbit model</td>
<td align="center" style="background-color:#FFFFFF">Human clot in a rat model</td>
<td align="center" style="background-color:#FFFFFF">Autologous clot in a rat model</td>
<td align="center" style="background-color:#FFFFFF">Filament occlusion in a rat model<break/>microvascular impairment</td>
<td align="center" style="background-color:#FFFFFF">Autologous clot in a rabbit model</td>
<td align="center" style="background-color:#FFFFFF">Human clot in a rabbit model</td>
<td align="center" style="background-color:#FFFFFF">Human clot in a rabbit model</td>
<td align="center" style="background-color:#FFFFFF">Autologous clot in a rabbit model</td>
<td align="center" style="background-color:#FFFFFF">Autologous clot in a rabbit model</td>
<td align="center" style="background-color:#FFFFFF">Autologous clot in a swine model</td>
<td align="center" style="background-color:#FFFFFF">Autologous white clot in a rat model</td>
<td align="center" style="background-color:#FFFFFF">Autologous clot in a rat model</td>
<td align="center" style="background-color:#FFFFFF">Autologous red and white clot in a rat model</td>
<td align="center" style="background-color:#FFFFFF">Filament occlusion in a rat model<break/>microvascular impairment</td>
</tr>
<tr>
<td align="justify" style="background-color:#FFFFFF"><bold>Frequency</bold></td>
<td align="center" style="background-color:#FFFFFF">1 MHz</td>
<td align="center" style="background-color:#FFFFFF">1MHz</td>
<td align="center" style="background-color:#FFFFFF">800 kHz</td>
<td align="center" style="background-color:#FFFFFF">2MHz</td>
<td align="center" style="background-color:#FFFFFF">2MHz</td>
<td align="center" style="background-color:#FFFFFF">1 to 3 MHz</td>
<td align="center" style="background-color:#FFFFFF">1MHz</td>
<td align="center" style="background-color:#FFFFFF">1MHz</td>
<td align="center" style="background-color:#FFFFFF">1MHz</td>
<td align="center" style="background-color:#FFFFFF">800kHz</td>
<td align="center" style="background-color:#FFFFFF">2MHz</td>
<td align="center" style="background-color:#FFFFFF">1.6MHz</td>
<td align="center" style="background-color:#FFFFFF">3MHz</td>
<td align="center" style="background-color:#FFFFFF">1MHz</td>
<td align="center" style="background-color:#FFFFFF">2MHz</td>
<td align="center" style="background-color:#FFFFFF">3MHz</td>
</tr>
<tr>
<td align="justify" style="background-color:#FFFFFF"><bold>Transducer geometry</bold></td>
<td align="center" style="background-color:#FFFFFF">Focused (5 mm) cylindrical beam<break/>10 cm2</td>
<td align="center" style="background-color:#FFFFFF">Focused (5 mm) cylindrical beam<break/>10 cm2</td>
<td align="center" style="background-color:#FFFFFF">2 cm diameter transducer</td>
<td align="center" style="background-color:#FFFFFF">Imaging probe (P4-2, Philips®) focused (5cm)</td>
<td align="center" style="background-color:#FFFFFF">Doppler probe (DWL®)</td>
<td align="center" style="background-color:#FFFFFF">Imaging probe (Sonos 7500; Philips®)</td>
<td align="center" style="background-color:#FFFFFF">Focused (5 mm) cylindrical beam<break/>10 cm2</td>
<td align="center" style="background-color:#FFFFFF">Focused (5 mm) cylindrical beam<break/>10 cm2</td>
<td align="center" style="background-color:#FFFFFF">Focused (5 mm) cylindrical beam<break/>10 cm2</td>
<td align="center" style="background-color:#FFFFFF">transducer of 2.8cm2</td>
<td align="center" style="background-color:#FFFFFF">Doppler probe (DWL®), 25-30mm depth, sampling volume of 10 mm<sup>3</sup></td>
<td align="center" style="background-color:#FFFFFF">Imaging probe (S5-1, Philips®) focused (3cm)</td>
<td align="center" style="background-color:#FFFFFF">Imaging probe (Sonos 7500; Philips®)</td>
<td align="center" style="background-color:#FFFFFF">Imaging probe (S5-1, Philips®)</td>
<td align="center" style="background-color:#FFFFFF">Imaging probe (4V1C Acuson® sequoia)</td>
<td align="center" style="background-color:#FFFFFF">Imaging probe (Sonos 7500; Philips®), focused at 57 mm.</td>
</tr>
<tr>
<td align="justify" style="background-color:#FFFFFF"><bold>Position of US probe</bold></td>
<td align="center" style="background-color:#FFFFFF">Temporal bone</td>
<td align="center" style="background-color:#FFFFFF">Temporal bone</td>
<td align="center" style="background-color:#FFFFFF">Behind the eye</td>
<td align="center" style="background-color:#FFFFFF">On carotid</td>
<td align="center" style="background-color:#FFFFFF">Parietal bone</td>
<td align="center" style="background-color:#FFFFFF">NA</td>
<td align="center" style="background-color:#FFFFFF">Temporal bone</td>
<td align="center" style="background-color:#FFFFFF">Temporal bone</td>
<td align="center" style="background-color:#FFFFFF">Temporal bone</td>
<td align="center" style="background-color:#FFFFFF">On carotid</td>
<td align="center" style="background-color:#FFFFFF">Right parietal bone</td>
<td align="center" style="background-color:#FFFFFF">Temporal bone</td>
<td align="center" style="background-color:#FFFFFF">40 mm above the skull</td>
<td align="center" style="background-color:#FFFFFF">Carotid through a human temporal bone</td>
<td align="center" style="background-color:#FFFFFF">Temporal</td>
<td align="center" style="background-color:#FFFFFF">NA</td>
</tr>
<tr>
<td align="justify" style="background-color:#FFFFFF"><bold>Duty cycle</bold></td>
<td align="center" style="background-color:#FFFFFF">20%</td>
<td align="center" style="background-color:#FFFFFF">20%</td>
<td align="center" style="background-color:#FFFFFF">20%</td>
<td align="center" style="background-color:#FFFFFF">5%</td>
<td align="center" style="background-color:#FFFFFF">1%</td>
<td align="center" style="background-color:#FFFFFF">NA</td>
<td align="center" style="background-color:#FFFFFF">20%</td>
<td align="center" style="background-color:#FFFFFF">20%</td>
<td align="center" style="background-color:#FFFFFF">20%</td>
<td align="center" style="background-color:#FFFFFF">20%</td>
<td align="center" style="background-color:#FFFFFF">NA</td>
<td align="center" style="background-color:#FFFFFF">0.01% or 0.04%</td>
<td align="center" style="background-color:#FFFFFF">NA</td>
<td align="center" style="background-color:#FFFFFF">NA</td>
<td align="center" style="background-color:#FFFFFF">NA</td>
<td align="center" style="background-color:#FFFFFF">NA</td>
</tr>
<tr>
<td align="justify" style="background-color:#FFFFFF"><bold>Power</bold></td>
<td align="center" style="background-color:#FFFFFF">2.2W/cm<sup>2</sup> (Isata)</td>
<td align="center" style="background-color:#FFFFFF">2W/cm<sup>2</sup> (Isata)</td>
<td align="center" style="background-color:#FFFFFF">2.4W/cm<sup>2</sup></td>
<td align="center" style="background-color:#FFFFFF">NA</td>
<td align="center" style="background-color:#FFFFFF">500mW/cm<sup>2</sup> (Ispta)</td>
<td align="center" style="background-color:#FFFFFF">NA</td>
<td align="center" style="background-color:#FFFFFF">0.8W/cm<sup>2</sup> (Isata)</td>
<td align="center" style="background-color:#FFFFFF">0.8W/cm<sup>2</sup> (Isata)</td>
<td align="center" style="background-color:#FFFFFF">0.8W/cm<sup>2</sup> (Isata)</td>
<td align="center" style="background-color:#FFFFFF">2.787W/cm<sup>2</sup></td>
<td align="center" style="background-color:#FFFFFF">252mW/cm<sup>2</sup> (Ispta)</td>
<td align="center" style="background-color:#FFFFFF">NA</td>
<td align="center" style="background-color:#FFFFFF">NA</td>
<td align="center" style="background-color:#FFFFFF">NA</td>
<td align="center" style="background-color:#FFFFFF">NA</td>
<td align="center" style="background-color:#FFFFFF">NA</td>
</tr>
<tr>
<td align="justify" style="background-color:#FFFFFF"><bold>Negative peak pressure</bold></td>
<td align="center" style="background-color:#FFFFFF">NA</td>
<td align="center" style="background-color:#FFFFFF">NA</td>
<td align="center" style="background-color:#FFFFFF">NA</td>
<td align="center" style="background-color:#FFFFFF">1.56 MPa</td>
<td align="center" style="background-color:#FFFFFF">2MPa</td>
<td align="center" style="background-color:#FFFFFF">1.7 to 2.94 MPa</td>
<td align="center" style="background-color:#FFFFFF">0.1575MPa</td>
<td align="center" style="background-color:#FFFFFF">NA</td>
<td align="center" style="background-color:#FFFFFF">0.1575MPa</td>
<td align="center" style="background-color:#FFFFFF">NA</td>
<td align="center" style="background-color:#FFFFFF">NA</td>
<td align="center" style="background-color:#FFFFFF">2.15 or 2.65 MPa</td>
<td align="center" style="background-color:#FFFFFF">2,94 MPa</td>
<td align="center" style="background-color:#FFFFFF">0.9 MPa</td>
<td align="center" style="background-color:#FFFFFF">2.68 MPa</td>
<td align="center" style="background-color:#FFFFFF">2.94 MPa</td>
</tr>
<tr>
<td align="justify" style="background-color:#FFFFFF"><bold>Mechanical index</bold></td>
<td align="center" style="background-color:#FFFFFF">NA</td>
<td align="center" style="background-color:#FFFFFF">NA</td>
<td align="center" style="background-color:#FFFFFF">NA</td>
<td align="center" style="background-color:#FFFFFF">1.3</td>
<td align="center" style="background-color:#FFFFFF">1.41</td>
<td align="center" style="background-color:#FFFFFF">1.7</td>
<td align="center" style="background-color:#FFFFFF">0.16</td>
<td align="center" style="background-color:#FFFFFF">NA</td>
<td align="center" style="background-color:#FFFFFF">0.16</td>
<td align="center" style="background-color:#FFFFFF">NA</td>
<td align="center" style="background-color:#FFFFFF">NA</td>
<td align="center" style="background-color:#FFFFFF">1.7 or 2.1</td>
<td align="center" style="background-color:#FFFFFF">1.7</td>
<td align="center" style="background-color:#FFFFFF">0.9</td>
<td align="center" style="background-color:#FFFFFF">1.9</td>
<td align="center" style="background-color:#FFFFFF">1.7</td>
</tr>
<tr>
<td align="justify" style="background-color:#FFFFFF"><bold>Pulse duration</bold></td>
<td align="center" style="background-color:#FFFFFF">2 msec</td>
<td align="center" style="background-color:#FFFFFF">2 msec</td>
<td align="center" style="background-color:#FFFFFF">4 msec</td>
<td align="center" style="background-color:#FFFFFF">0.33msec</td>
<td align="center" style="background-color:#FFFFFF">0.2msec</td>
<td align="center" style="background-color:#FFFFFF">NA</td>
<td align="center" style="background-color:#FFFFFF">2 msec</td>
<td align="center" style="background-color:#FFFFFF">2 msec</td>
<td align="center" style="background-color:#FFFFFF">2 msec</td>
<td align="center" style="background-color:#FFFFFF">NA</td>
<td align="center" style="background-color:#FFFFFF">NA</td>
<td align="center" style="background-color:#FFFFFF">0.005 or 0.020 msec</td>
<td align="center" style="background-color:#FFFFFF">NA</td>
<td align="center" style="background-color:#FFFFFF">NA</td>
<td align="center" style="background-color:#FFFFFF">NA</td>
<td align="center" style="background-color:#FFFFFF">NA</td>
</tr>
<tr>
<td align="justify" style="background-color:#FFFFFF"><bold>Pulse repetition frequency</bold></td>
<td align="center" style="background-color:#FFFFFF">100 Hz</td>
<td align="center" style="background-color:#FFFFFF">100 Hz</td>
<td align="center" style="background-color:#FFFFFF">50 Hz</td>
<td align="center" style="background-color:#FFFFFF">150 Hz</td>
<td align="center" style="background-color:#FFFFFF">50Hz</td>
<td align="center" style="background-color:#FFFFFF">NA</td>
<td align="center" style="background-color:#FFFFFF">100 Hz</td>
<td align="center" style="background-color:#FFFFFF">100 Hz</td>
<td align="center" style="background-color:#FFFFFF">100 Hz</td>
<td align="center" style="background-color:#FFFFFF">NA</td>
<td align="center" style="background-color:#FFFFFF">NA</td>
<td align="center" style="background-color:#FFFFFF">8 Hz</td>
<td align="center" style="background-color:#FFFFFF">NA</td>
<td align="center" style="background-color:#FFFFFF">NA</td>
<td align="center" style="background-color:#FFFFFF">NA</td>
<td align="center" style="background-color:#FFFFFF">NA</td>
</tr>
<tr>
<td align="justify" style="background-color:#FFFFFF"><bold>Total treatment Duration (US)</bold></td>
<td align="center" style="background-color:#FFFFFF">24 min</td>
<td align="center" style="background-color:#FFFFFF">24 min</td>
<td align="center" style="background-color:#FFFFFF">30 min</td>
<td align="center" style="background-color:#FFFFFF">30 min</td>
<td align="center" style="background-color:#FFFFFF">30 min</td>
<td align="center" style="background-color:#FFFFFF">60 min</td>
<td align="center" style="background-color:#FFFFFF">60 min</td>
<td align="center" style="background-color:#FFFFFF">60 min</td>
<td align="center" style="background-color:#FFFFFF">60 min</td>
<td align="center" style="background-color:#FFFFFF">30 min</td>
<td align="center" style="background-color:#FFFFFF">120 min</td>
<td align="center" style="background-color:#FFFFFF">30 min</td>
<td align="center" style="background-color:#FFFFFF">60 min</td>
<td align="center" style="background-color:#FFFFFF">20 min</td>
<td align="center" style="background-color:#FFFFFF">30 min</td>
<td align="center">60 minutes</td>
</tr>
</tbody>
</table>
</alternatives>
<table-wrap-foot>
<fn id="t005fn001"><p>MI: Mechanical index; NA: Not available; Isata: spatial average temporal average intensity; Ispta: Spatial peak temporal average intensity.</p></fn>
</table-wrap-foot>
</table-wrap>
</sec>
<sec id="sec014">
<title>Thrombolytic drugs co-administered with the microbubbles</title>
<p><xref ref-type="table" rid="pone.0191788.t004">Table 4</xref> summarizes the thrombolytic drugs co-administered with the MB.</p>
</sec>
<sec id="sec015">
<title>Evaluation criteria</title>
<sec id="sec016">
<title>Efficacy</title>
<p>TIMI (Thrombolysis in Myocardial Infarction), TIBI (Thrombolysis in Brain Infarction), custom patency, or de-clotting scores were used to assess the quality of arterial recanalization with angiography [<xref ref-type="bibr" rid="pone.0191788.ref018">18</xref>, <xref ref-type="bibr" rid="pone.0191788.ref019">19</xref>, <xref ref-type="bibr" rid="pone.0191788.ref024">24</xref>–<xref ref-type="bibr" rid="pone.0191788.ref026">26</xref>]. Gao et al. [<xref ref-type="bibr" rid="pone.0191788.ref020">20</xref>] used MRI to assess restoration of blood flow. Ren et al. [<xref ref-type="bibr" rid="pone.0191788.ref030">30</xref>] used US imaging and pulsed wave Doppler to assess recanalization. Other coagulation parameters used included activated partial thromboplastin time [<xref ref-type="bibr" rid="pone.0191788.ref026">26</xref>], activated clotting time [<xref ref-type="bibr" rid="pone.0191788.ref019">19</xref>], prothrombin time [<xref ref-type="bibr" rid="pone.0191788.ref026">26</xref>], fibrinogen [<xref ref-type="bibr" rid="pone.0191788.ref026">26</xref>, <xref ref-type="bibr" rid="pone.0191788.ref027">27</xref>] and D-dimer [<xref ref-type="bibr" rid="pone.0191788.ref026">26</xref>]. Alonso et al. and Tomkins et al. [<xref ref-type="bibr" rid="pone.0191788.ref027">27</xref>, <xref ref-type="bibr" rid="pone.0191788.ref031">31</xref>] examined thrombi in treated arteries using histology. Liu et al. [<xref ref-type="bibr" rid="pone.0191788.ref024">24</xref>] determined changes in S100B astroglial protein levels in blood were a marker of cerebral damage [<xref ref-type="bibr" rid="pone.0191788.ref034">34</xref>]. Diffusion-weighted sequences and phosphorus spectroscopy were used by Moumouh et al. [<xref ref-type="bibr" rid="pone.0191788.ref029">29</xref>] to assess and to quantify the extent of cerebral infarct. Nedelmann et al. [<xref ref-type="bibr" rid="pone.0191788.ref032">32</xref>] used MRI T2 relaxation time as indicator of edema formation. Cerebral infarct volume was assessed by eight studies as a treatment outcome [<xref ref-type="bibr" rid="pone.0191788.ref021">21</xref>–<xref ref-type="bibr" rid="pone.0191788.ref025">25</xref>, <xref ref-type="bibr" rid="pone.0191788.ref028">28</xref>, <xref ref-type="bibr" rid="pone.0191788.ref031">31</xref>, <xref ref-type="bibr" rid="pone.0191788.ref032">32</xref>]. Nedelmann et al. and Schleicher et al. [<xref ref-type="bibr" rid="pone.0191788.ref032">32</xref>, <xref ref-type="bibr" rid="pone.0191788.ref033">33</xref>] evaluated vascular volumes with microcomputed tomography. Finally, four studies [<xref ref-type="bibr" rid="pone.0191788.ref021">21</xref>, <xref ref-type="bibr" rid="pone.0191788.ref022">22</xref>, <xref ref-type="bibr" rid="pone.0191788.ref028">28</xref>, <xref ref-type="bibr" rid="pone.0191788.ref032">32</xref>] used functional tests (as a marker of neurological improvement) after STL or rtPA-STL treatment.</p>
</sec>
<sec id="sec017">
<title>Safety</title>
<p>Nine studies used histological analysis to assess intracranial hemorrhage (ICH) [<xref ref-type="bibr" rid="pone.0191788.ref020">20</xref>–<xref ref-type="bibr" rid="pone.0191788.ref025">25</xref>, <xref ref-type="bibr" rid="pone.0191788.ref028">28</xref>, <xref ref-type="bibr" rid="pone.0191788.ref032">32</xref>, <xref ref-type="bibr" rid="pone.0191788.ref033">33</xref>].</p>
</sec>
</sec>
<sec id="sec018">
<title>Treatment outcomes</title>
<p><xref ref-type="table" rid="pone.0191788.t006">Table 6</xref> summarizes the treatment conditions and corresponding treatment outcomes of the 16 studies.</p>
<table-wrap id="pone.0191788.t006" position="float">
<object-id pub-id-type="doi">10.1371/journal.pone.0191788.t006</object-id>
<label>Table 6</label> <caption><title>Conditions undergoing testing and main outcomes (p &lt; 0.05) of the 16 studies.</title></caption>
<alternatives>
<graphic id="pone.0191788.t006g" mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pone.0191788.t006" xlink:type="simple"/>
<table>
<colgroup>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
</colgroup>
<thead>
<tr>
<th align="left"> </th>
<th align="left">References</th>
<th align="left">Conditions tested</th>
<th align="left">Positive outcomes (criteria)</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" rowspan="5"><bold>STL efficacy</bold></td>
<td align="left">Wang et al. (2008)</td>
<td align="left">- IA TSTL<break/>- IA saline control<break/>- IV TSTL<break/>- IV STL<break/>- US</td>
<td align="left">- IA TSTL&gt; IV TSTL (declotting time, success rate)<break/>- IA or IV TSTL &gt; US (declotting time, and TIMI)<break/>- IA or IV TSTL &gt; IA saline control<break/>- IV TSTL &gt; IV STL (declotting time, TIMI)</td>
</tr>
<tr>
<td align="left">Moumouh et al. (2010)</td>
<td align="left">- STL<break/>- RtPA</td>
<td align="left">- STL &gt; RtPA (Pcr/Pi (estimation of the oxidative phosphorylation metabolism))</td>
</tr>
<tr>
<td align="left">Alonso et al. (2009)</td>
<td align="left">- IV STL with TMB<break/>- IV STL<break/>- Saline/US</td>
<td align="left">- IV STL with TMB &gt; IV STL (D-Dimer)<break/>- IV STL with TMB &gt; US (D-Dimer)</td>
</tr>
<tr>
<td align="left">Culp et al. (2003)</td>
<td align="left">- IA STL<break/>- IA Saline/US</td>
<td align="left">- IA STL &gt; IA Saline/US (declotting score, flow scores, success at 24 min)</td>
</tr>
<tr>
<td align="left">Culp et al. (2004)</td>
<td align="left">- IV TSTL<break/>- IV eptifibatide/US<break/>- IV saline/US</td>
<td align="left">- IV TSTL &gt; IV eptifibatide/US (angiographic success, declotting score)<break/>- IV TSTL &gt; IV saline/US (angiographic success, declotting score)</td>
</tr>
<tr>
<td align="left" rowspan="2"><bold>Efficacy of rtPA-STL</bold></td>
<td align="left">Tomkins et al. (2015)</td>
<td align="left">- RtPA<break/>- RtPA-STL<break/>- Saline</td>
<td align="left">No recanalization</td>
</tr>
<tr>
<td align="left">Ren et al. (2015)</td>
<td align="left">(1) Control<break/>(2) RtPA<break/>(3) STL<break/>(4) RtPA-STL<break/>(5) ½ RtPA-STL</td>
<td align="left">- After 10 min of treatment: RtPA-STL &gt; contrl; RtPA; STL (Recanalization rate)<break/>- After 20 min of treatment: All conditions (except STL) induced a significant recanalization versus control (recanalization rate)</td>
</tr>
<tr>
<td align="left" rowspan="4"><bold>Safety and efficacy of STL</bold></td>
<td align="left">Culp et al. (2011)</td>
<td align="left">- Control<break/>- RtPA<break/>- RtPA/US<break/>- Lipid STL<break/>- Albumin STL<break/>- TSTL</td>
<td align="left">- All MB STL &gt; control, rtPA (infarct volume, SB-100 rate), Pooled analysis with all type of MB (Lipid, Albumin, TMB)</td>
</tr>
<tr>
<td align="left">Liu et al. (2012)</td>
<td align="left">- Urokinase<break/>- Urokinase-STL</td>
<td align="left">- Urokinase-STL &gt; Urokinase (infarct volume)<break/>- Urokinase-STL &gt; Urokinase (mean flow velocity at 120 min)</td>
</tr>
<tr>
<td align="left">Ren et al. (2012)</td>
<td align="left">- IA STL<break/>- IA TSTL<break/>- IV STL<break/>- IV TSTL<break/>- IA rtPA<break/>- IA saline/US</td>
<td align="left">- IA TSTL &gt; IA Saline/US (patency score, TIBI)<break/>- IA TSTL &gt; IA STL (patency score, TIBI)<break/>- IA TSTL &gt; IA Saline/US (recanalization rate)<break/>- IA rtPA &gt; IA Saline/US (recanalization rate)<break/>- IA TSTL &gt; IA STL (recanalization rate)</td>
</tr>
<tr>
<td align="left">Gao et al. (2014)</td>
<td align="left">- (1) 1.7MHz, 1.7 MI, 20 μs pulse STL<break/>- (2) 1.6MHz, 2.4 MI, 5 μs pulse STL<break/>- (3) 1.6MHz, 2.4 MI, 5 μs pulse US</td>
<td align="left">- (2)&gt;(3) (after 24H, relatives changes in cerebral blood flow)<break/>- (2)&gt;(1) (complete recanalization of ipsi and contralateral internal carotid and middle cerebral artery)</td>
</tr>
<tr>
<td align="left" rowspan="5"><bold>Safety and efficacy of rtPA-STL</bold></td>
<td align="left">Nedelmann et al. (2010)</td>
<td align="left">Substudy 1: Efficacy<break/>- Euthanization directly after reperfusion (control 1)<break/>- Euthanization 60 min after reperfusion (control 2)<break/>- RtPA<break/>- RtPA-STL<break/>- STL<break/>- RtPA+US<break/>Substudy 2: Safety<break/>- RtPA<break/>- RtPA-STL<break/>Substudy 3: Temperature evaluation<break/>RtPA-STL</td>
<td align="left">Substudy 1: Comparison between right and left hemisphere: the right hemisphere is submitted to a transient vascular occlusion of the middle cerebral artery.<break/>- Control 1 &gt; healthy hemisphere (impaired vascular volume p&lt;0.001)<break/>- Control 2 &gt; healthy hemisphere (impaired vascular volume p&lt;0.001)<break/>- RtPA &gt; healthy hemisphere (impaired vascular volume, p&lt;0.003)<break/>- RtPA-STL = Healthy hemisphere (impaired vascular volume, p&lt;0.6)<break/>- US &gt; healthy hemisphere (impaired vascular volume, p&lt;0.001)<break/>- STL &gt; healthy hemisphere (impaired vascular volume, p&lt;0.04)<break/>Substudy 2:<break/>- RtPA-STL &gt; RtPA (infarct volume, p&lt;0.05)<break/>- RtPA-STL &gt; RtPA (T2 relaxation, indicator of cerebral edema, p&lt;0.05)<break/>Substudy 3:<break/>- No significant change of temperature from baseline</td>
</tr>
<tr>
<td align="left">Brown et al. (2011)</td>
<td align="left">- control/US +/-MB<break/>- RtPA (0.1mg/kg) /US +/-MB<break/>- RtPA (0.3mg/kg) /US +/-MB<break/>- RtPA (0.8mg/kg) /US +/-MB<break/>- RtPA (0.9mg/kg) /US +/-MB</td>
<td align="left">- RtPA<xref ref-type="table-fn" rid="t006fn002">*</xref>-STL &gt; control/US/MB (infarct volume)<break/>- RtPA(0.8–0.9mg/kg)-STL&gt; RtPA(0.8–0.9mg/kg) (lower ICH incidence)<break/>- RtPA<xref ref-type="table-fn" rid="t006fn002">*</xref>-STL &gt; RtPA (all concentrations) (lower ICH incidence)<break/>- US/MB &gt; control (infarct volume)<break/>- RtPA<xref ref-type="table-fn" rid="t006fn002">*</xref>-STL&gt; control (infarct volume)<break/>- RtPA<xref ref-type="table-fn" rid="t006fn002">*</xref>-STL&gt; rtPA<xref ref-type="table-fn" rid="t006fn002">*</xref> (reduced ICH incidence outside of strokes)</td>
</tr>
<tr>
<td align="left">Flores et al. (2011)</td>
<td align="left">- Control<break/>- US<break/>- RtPA<break/>- RtPA/US<break/>- STL<break/>- RtPA-STL</td>
<td align="left">- STL &gt; RtPA/US; US; RtPA; RtPA-STL; control (decreased rate of ICH outside the infarct area)<break/>- RtPA/US; STL; RtPA; RtPA-STL &gt; US (infarct volume)</td>
</tr>
<tr>
<td align="left">Lu et al. (2016)</td>
<td align="left">- Control<break/>- STL<break/>- RtPA<break/>- RtPA-STL</td>
<td align="left">- STL &gt; control (red and white thrombi, cerebral infarct volume)<break/>- STL &gt; RtPA (red thrombi, cerebral infarct volume)<break/>- RtPA-STL &gt; RtPA (red thrombi, cerebral infarct volume)<break/>- STL &gt; control (red and white thrombi, Neuroscore)<break/>- STL &gt; RtPA (White thrombi, Neuroscore)</td>
</tr>
<tr>
<td align="left">Schleicher et al. (2016)</td>
<td align="left">- Control<break/>- RtPA<break/>- RtPA-STL with 1/3 dose of MB<break/>- RtPA-STL with full dose of MB</td>
<td align="left">Comparison between right (transient vascular occlusion) and left (healthy) hemisphere<break/>- Control &gt; healthy hemisphere (impaired vascular volume, p&lt;0.05)<break/>- RtPA &gt; healthy hemisphere (impaired vascular volume, p&lt;0.05)<break/>- RtPA-STL full MB + RtPA-STL 1/3MB = healthy hemisphere (impaired vascular volume, p&gt;0.05)<break/>Comparison between condition<break/>- RtPA-STL full MB &gt; Control (ischemic lesion volume, p = 0.044)</td>
</tr>
</tbody>
</table>
</alternatives>
<table-wrap-foot>
<fn id="t006fn001"><p>TSTL = STL using Targeted Microbubbles (TMB).</p></fn>
<fn id="t006fn002"><p>*Pooled analysis considering all concentrations of rtPA.</p></fn>
</table-wrap-foot>
</table-wrap>
<sec id="sec019">
<title>Efficacy</title>
<p>Three studies [<xref ref-type="bibr" rid="pone.0191788.ref018">18</xref>, <xref ref-type="bibr" rid="pone.0191788.ref025">25</xref>, <xref ref-type="bibr" rid="pone.0191788.ref026">26</xref>] used intra-arterial (IA) administration of MBs. Wang et al. [<xref ref-type="bibr" rid="pone.0191788.ref026">26</xref>] showed that STL using IA administration of targeted microbubbles (TMBs) produced superior de-clotting scores as compared to IV injection of TMBs. Similarly, Ren et al. [<xref ref-type="bibr" rid="pone.0191788.ref025">25</xref>] showed that TMBs induced better TIBI patency scores and efficient recanalization rates than IA administered non-targeted MBs. Culp et al. [<xref ref-type="bibr" rid="pone.0191788.ref019">19</xref>] obtained better de-clotting scores for STL using TMBs when compared to US + eptifibatide and US + saline. Using D-dimer dosage, Alonso et al. [<xref ref-type="bibr" rid="pone.0191788.ref027">27</xref>] demonstrated that rtPA-STL with TMBs caused higher efficient thrombi disintegration than STL or US alone. Culp et al. [<xref ref-type="bibr" rid="pone.0191788.ref022">22</xref>] reported lower infarct volume for STL with TMBs when compared to untreated controls. Nedelmann et al. and Shleicher et al. [<xref ref-type="bibr" rid="pone.0191788.ref032">32</xref>, <xref ref-type="bibr" rid="pone.0191788.ref033">33</xref>] found no significant difference between the vascular volume of the hemisphere that experienced transient ischemia and rtPA-STL when compared to the healthy hemisphere.</p>
<p>With regard to brain damage, Brown et al. [<xref ref-type="bibr" rid="pone.0191788.ref021">21</xref>] noted a significant reduction in infarct brain volume for rtPA-STL when compared to STL or control animals. Similarly, Lu et al. [<xref ref-type="bibr" rid="pone.0191788.ref028">28</xref>] reported a reduction in infarct brain volume for STL and rtPA-STL on white microthrombi compared to rtPA alone and rtPA-STL on red microthrombi compared to rtPA alone. Moreover, Liu et al. [<xref ref-type="bibr" rid="pone.0191788.ref024">24</xref>] described a significant reduction in infarct brain volume for STL + urokinase when compared to urokinase treatment alone (p = 0.025). Nedelmann et al. [<xref ref-type="bibr" rid="pone.0191788.ref032">32</xref>] showed a lower infarct volume with a lower edema volume using rtPA-STL compared to rtPA treatment alone. In addition, Schleicher et al. [<xref ref-type="bibr" rid="pone.0191788.ref033">33</xref>] reported also a lower infarct volume using rtPA-STL compared to rtPA alone. Ren et al. [<xref ref-type="bibr" rid="pone.0191788.ref030">30</xref>] reported improved recanalization rates with rtPA-STL as compared to STL alone or rtPA alone after 10 minutes of treatment. However, Tomkins et al. [<xref ref-type="bibr" rid="pone.0191788.ref031">31</xref>] reported a complete absence of recanalization for rtPA-STL treatment on platelet-rich thrombi. In addition, functional tests performed in the studies by Brown et al., Culp et al., and Lu et al. [<xref ref-type="bibr" rid="pone.0191788.ref021">21</xref>, <xref ref-type="bibr" rid="pone.0191788.ref022">22</xref>, <xref ref-type="bibr" rid="pone.0191788.ref028">28</xref>] showed no noticeable differences between treatment regimens. Nevertheless, Lu et al. [<xref ref-type="bibr" rid="pone.0191788.ref028">28</xref>] reported better neurological scores for STL when compared to rtPA alone for the treatment of white microthrombi emboli.</p>
</sec>
<sec id="sec020">
<title>Safety</title>
<p>Flores et al. [<xref ref-type="bibr" rid="pone.0191788.ref023">23</xref>] reported fewer hemorrhages outside the infarct zone for STL when compared to rtPA-STL, US + rtPA, rtPA alone, and US alone (<italic>p</italic> &lt; 0.004). Brown et al. [<xref ref-type="bibr" rid="pone.0191788.ref021">21</xref>] found lower incidences of ICH not only for rtPA-STL compared to rtPA alone but also for the rtPA concentration of 0.8–0.9 mg/kg. The authors also reported reduced incidence of ICH outside of stroke zones when using rtPA-STL in comparison to rtPA (<italic>p</italic> = 0.005) alone, when the results obtained with all concentrations of rtPA were combined. All other studies showed no noticeable differences in the incidence of cerebral hemorrhage using rtPA-STL, STL alone, and rtPA alone.</p>
</sec>
</sec>
<sec id="sec021">
<title>Quality assessment</title>
<p>The average CAMARADES criteria were 4.68 (± 1.08) for the 10 criteria tested, as summarized in <xref ref-type="table" rid="pone.0191788.t007">Table 7</xref>.</p>
<table-wrap id="pone.0191788.t007" position="float">
<object-id pub-id-type="doi">10.1371/journal.pone.0191788.t007</object-id>
<label>Table 7</label> <caption><title>Quality assessment of the studies using the collaborative approach to meta-analysis and review of Animal Data from Experimental Studies (CAMARADES) checklist items.</title></caption>
<alternatives>
<graphic id="pone.0191788.t007g" mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pone.0191788.t007" xlink:type="simple"/>
<table>
<colgroup>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
</colgroup>
<thead>
<tr>
<th align="left">CAMARADES CHECKLIST</th>
<th align="left">Culp et al. (2003)</th>
<th align="left">Culp et al. (2004)</th>
<th align="left">Wang et al. (2008)</th>
<th align="left">Alonso et al. (2009)</th>
<th align="left">Moumouh et al. (2010)</th>
<th align="left">Nedelmann et al. (2010)</th>
<th align="left">Culp et al. (2011)</th>
<th align="left">Brown et al. (2011)</th>
<th align="left">Flores et al. (2011)</th>
<th align="left">Ren et al. (2012)</th>
<th align="left">Liu et al. (2012)</th>
<th align="left">Gao et al. (2014)</th>
<th align="left">Tomkins et al. (2015)</th>
<th align="left">Ren et al. (2015)</th>
<th align="left">Lu et al. (2016)</th>
<th align="left">Schleicher et al. (2016)</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left"><bold>Publication in peer-reviewed journal</bold></td>
<td align="center">Y</td>
<td align="center">Y</td>
<td align="center">Y</td>
<td align="center">Y</td>
<td align="center">Y</td>
<td align="center">Y</td>
<td align="center">Y</td>
<td align="center">Y</td>
<td align="center">Y</td>
<td align="center">Y</td>
<td align="center">Y</td>
<td align="center">Y</td>
<td align="center">Y</td>
<td align="center">Y</td>
<td align="center">Y</td>
<td align="center">Y</td>
</tr>
<tr>
<td align="left"><bold>Statement of control of temperature</bold></td>
<td align="center">N</td>
<td align="center">N</td>
<td align="center">N</td>
<td align="center">Y</td>
<td align="center">Y</td>
<td align="center">Y</td>
<td align="center">N</td>
<td align="center">N</td>
<td align="center">N</td>
<td align="center">N</td>
<td align="center">N</td>
<td align="center">Y</td>
<td align="center">Y</td>
<td align="center">N</td>
<td align="center">N</td>
<td align="center">Y</td>
</tr>
<tr>
<td align="left"><bold>Randomization of treatment or control</bold></td>
<td align="center">Y</td>
<td align="center">Y</td>
<td align="center">Y</td>
<td align="center">N</td>
<td align="center">N</td>
<td align="center">N</td>
<td align="center">Y</td>
<td align="center">Y</td>
<td align="center">Y</td>
<td align="center">Y</td>
<td align="center">Y</td>
<td align="center">Y</td>
<td align="center">N</td>
<td align="center">N</td>
<td align="center">N</td>
<td align="center">N</td>
</tr>
<tr>
<td align="left"><bold>Allocation concealment</bold></td>
<td align="center">Y</td>
<td align="center">N</td>
<td align="center">N</td>
<td align="center">N</td>
<td align="center">N</td>
<td align="center">N</td>
<td align="center">N</td>
<td align="center">N</td>
<td align="center">N</td>
<td align="center">N</td>
<td align="center">N</td>
<td align="center">N</td>
<td align="center">N</td>
<td align="center">N</td>
<td align="center">N</td>
<td align="center">N</td>
</tr>
<tr>
<td align="left"><bold>Blinded assessment of outcome</bold></td>
<td align="center">Y</td>
<td align="center">N</td>
<td align="center">Y</td>
<td align="center">N</td>
<td align="center">N</td>
<td align="center">Y</td>
<td align="center">N</td>
<td align="center">Y</td>
<td align="center">N</td>
<td align="center">Y</td>
<td align="center">N</td>
<td align="center">N</td>
<td align="center">N</td>
<td align="center">N</td>
<td align="center">N</td>
<td align="center">Y</td>
</tr>
<tr>
<td align="left"><bold>Avoidance of anesthetics with marked intrinsic properties</bold></td>
<td align="center">Y</td>
<td align="center">Y</td>
<td align="center">Y</td>
<td align="center">Y</td>
<td align="center">Y</td>
<td align="center">Y</td>
<td align="center">N</td>
<td align="center">Y</td>
<td align="center">N</td>
<td align="center">Y</td>
<td align="center">N</td>
<td align="center">N</td>
<td align="center">Y</td>
<td align="center">N</td>
<td align="center">Y</td>
<td align="center">Y</td>
</tr>
<tr>
<td align="left"><bold>Use of animals with hypertension or diabetes</bold></td>
<td align="center">N</td>
<td align="center">N</td>
<td align="center">N</td>
<td align="center">N</td>
<td align="center">N</td>
<td align="center">N</td>
<td align="center">N</td>
<td align="center">N</td>
<td align="center">N</td>
<td align="center">N</td>
<td align="center">N</td>
<td align="center">N</td>
<td align="center">Y</td>
<td align="center">N</td>
<td align="center">N</td>
<td align="center">N</td>
</tr>
<tr>
<td align="left"><bold>Sample size calculation</bold></td>
<td align="center">N</td>
<td align="center">N</td>
<td align="center">N</td>
<td align="center">N</td>
<td align="center">N</td>
<td align="center">N</td>
<td align="center">N</td>
<td align="center">N</td>
<td align="center">N</td>
<td align="center">N</td>
<td align="center">N</td>
<td align="center">N</td>
<td align="center">N</td>
<td align="center">N</td>
<td align="center">N</td>
<td align="center">N</td>
</tr>
<tr>
<td align="left"><bold>Statement of compliance with regulatory requirements</bold></td>
<td align="center">Y</td>
<td align="center">Y</td>
<td align="center">Y</td>
<td align="center">Y</td>
<td align="center">Y</td>
<td align="center">Y</td>
<td align="center">Y</td>
<td align="center">Y</td>
<td align="center">Y</td>
<td align="center">Y</td>
<td align="center">Y</td>
<td align="center">Y</td>
<td align="center">Y</td>
<td align="center">N</td>
<td align="center">Y</td>
<td align="center">Y</td>
</tr>
<tr>
<td align="left"><bold>Statement regarding possible conflict of interest</bold></td>
<td align="center">N</td>
<td align="center">N</td>
<td align="center">N</td>
<td align="center">Y</td>
<td align="center">N</td>
<td align="center">Y</td>
<td align="center">Y</td>
<td align="center">N</td>
<td align="center">N</td>
<td align="center">Y</td>
<td align="center">Y</td>
<td align="center">N</td>
<td align="center">Y</td>
<td align="center">N</td>
<td align="center">Y</td>
<td align="center">Y</td>
</tr>
<tr>
<td align="left"><bold>Total (on 10)</bold></td>
<td align="center">6</td>
<td align="center">4</td>
<td align="center">5</td>
<td align="center">5</td>
<td align="center">4</td>
<td align="center">6</td>
<td align="center">4</td>
<td align="center">5</td>
<td align="center">3</td>
<td align="center">6</td>
<td align="center">4</td>
<td align="center">4</td>
<td align="center">6</td>
<td align="center">3</td>
<td align="center">4</td>
<td align="center">6</td>
</tr>
</tbody>
</table>
</alternatives>
</table-wrap>
<p>Owing to considerable heterogeneity in the reported methods and data, meta-analysis was not feasible. As a result, no statistical examination was performed.</p>
</sec>
</sec>
<sec id="sec022" sec-type="conclusions">
<title>Discussion</title>
<sec id="sec023">
<title>Efficacy</title>
<p>This systematic review highlights a number of positive outcomes in terms of efficacy. Numerous criteria are evaluated throughout the studies. Half of the studies (8 of 16) assess cerebral infarct volume, while four studies use functional recovery tests and neurological scores. The most commonly used criteria are the recanalization rate and the quality of the vascular flow stream. However, discordances have been reported between apparent positive recanalization and favorable outcomes. Ren et al. [<xref ref-type="bibr" rid="pone.0191788.ref025">25</xref>] highlight the limit of this pure blood flow restoration assessment by showing a significant difference in recanalization scores and quality of the flow stream, but not in the infarcted brain volume. Infarcted brain volume and neurological score are the two main outcomes used in clinical trials to assess thrombolytic therapy [<xref ref-type="bibr" rid="pone.0191788.ref002">2</xref>–<xref ref-type="bibr" rid="pone.0191788.ref004">4</xref>]. Similar results are described in humans in the CLOTBUST (Combined Lysis Of Thrombus in Brain ischemia using transcranial Ultrasound and Systemic TPA) study [<xref ref-type="bibr" rid="pone.0191788.ref035">35</xref>], which has raised the need to consider clinical outcome as the pivotal end-point for all studies. This observation is in line with the Stroke Therapy Academic Industry Roundtable (STAIR) group recommendations [<xref ref-type="bibr" rid="pone.0191788.ref036">36</xref>].</p>
<p>Different stroke models are used to investigate the efficacy of STL—13 studies assess it on a thromboembolic model with a blood clot, and 3 studies assess it on microvasculature impairment (transient occlusion or microthrombi emboli). It appears that a clear benefit exists with the use of rtPA-STL in microvasculature impairment (transient occlusion and red or white micro-thrombi) compared to control or rtPA alone. White thrombi seem to be more resistant to STL or rtPA-STL [<xref ref-type="bibr" rid="pone.0191788.ref031">31</xref>]. Studies involving a thromboembolic model, present more heterogeneous results, as only 3 studies demonstrated a benefit of STL or rtPA-STL versus rtPA alone on clinical criteria. These discrepancies can be partly due to the variation in treatment initiation times highlighted in this review. Indeed, ischemia induce an inflammatory response in the salvageable penumbra area which is responsible for the secondary necrosis of this area [<xref ref-type="bibr" rid="pone.0191788.ref037">37</xref>]. Furthermore, this response could also lead to a reperfusion injury syndrome inducing oedema and hemorrhages [<xref ref-type="bibr" rid="pone.0191788.ref038">38</xref>]. These phenomenon are presumably absent immediately after vascular occlusion [<xref ref-type="bibr" rid="pone.0191788.ref039">39</xref>].</p>
<p>In terms of MBs used and US parameters, TMBs (Targeted Microbubbles) are more efficient than MBs, but none of the studies have tested the association of rtPA-TMBs (rtPA associated with TMB) versus rtPA. With the data available, one cannot conclude on the clinical interest of TMBs. Further investigations are required to evaluate the therapeutic efficacy of TMBs for the STL. The heterogeneity of US parameters used does not allow us to conclude which combination is the more efficient or if a specific combination of US parameters is giving better benefit to risk ratio in the specific pathophysiology of stroke. The only parameter between studies that seems to be consensual is the use of an US frequency predominantly in the Megahertz (MHz) range, probably to avoid standing waves [<xref ref-type="bibr" rid="pone.0191788.ref040">40</xref>] which has been supposed to be responsible of a high rate of ICH through an augmentation of peak negative pressure in the Transcranial Low-Frequency Ultrasound-Mediated Thrombolysis in Brain Ischemia (TRUMBI) study with the use of a US frequency of 300 kiloHertz (kHz) wi wi thout MBs in humans [<xref ref-type="bibr" rid="pone.0191788.ref041">41</xref>].</p>
</sec>
<sec id="sec024">
<title>Safety</title>
<p>Existing clinical STL data has shown that cerebral hemorrhage is the major side effect in terms of safety. Two studies report that rtPA-STL leads to fewer cerebral hemorrhages outside the infarcted zone. These two studies show no significant efficacy of rtPA-STL versus rtPA alone [<xref ref-type="bibr" rid="pone.0191788.ref021">21</xref>, <xref ref-type="bibr" rid="pone.0191788.ref023">23</xref>]. Based on these limited results, it may be inappropriate to draw conclusions on the safety of STL or rtPA-STL versus rtPA alone; and more generally on the benefit to risk ratio of this therapeutic approach. Compared to clinical trials, the results reported in this review are surprising, as none of the studies revealed a higher rate of cerebral hemorrhage versus control, even with the use of rtPA alone, which is known to significantly increase the rates of cerebral hemorrhage in clinical studies [<xref ref-type="bibr" rid="pone.0191788.ref002">2</xref>]. Some hypotheses can be made to explain the following: publication bias (e.g., the absence of the publication of studies showing a higher rate of cerebral hemorrhage with STL), the use of animal models with no risk factor of bleeding (e.g., aging or hypertension), and the absence of ischemia before treatment.</p>
</sec>
<sec id="sec025">
<title>Clinical translation/perspectives</title>
<p>The studies reviewed in this report use a thromboembolic stroke model or a microvasculature impairment model (by transient ischemia or deployment of microthrombi). Stroke in humans is due to different pathophysiological mechanisms associated with cardiovascular (CV) risk factors that are summarized in the TOAST (Trial of ORG 10172 in Acute Stroke Treatment) classification [<xref ref-type="bibr" rid="pone.0191788.ref042">42</xref>]. The use of an animal model closer phylogenetically to humans, such as gyrencephalic species, associated with CV risk factors (e.g., aging and hypertension) could bring more consistent data, as suggested by the recommendations for animal testing in stroke [<xref ref-type="bibr" rid="pone.0191788.ref036">36</xref>]. Some specificity of the human pathophysiology (e.g., the human skull) may be considered to ensure a clinical translation. Indeed, the interactions between the human skull and US beam are responsible for acoustic processes including standing waves, degradation of US focalization, and degradation of beam shape. High frequency ultrasound will also lead to more attenuation and heating [<xref ref-type="bibr" rid="pone.0191788.ref043">43</xref>]. These processes depend on the frequency used, the position of the US transducer, and the length of the US wave [<xref ref-type="bibr" rid="pone.0191788.ref044">44</xref>]. The TRUMBI trial [<xref ref-type="bibr" rid="pone.0191788.ref041">41</xref>] reports higher rates of cerebral hemorrhage, which are probably caused by standing waves. Standing waves field happens mainly with the use of low frequency US, and lower the cavitation threshold in comparison with a progressive wave field [<xref ref-type="bibr" rid="pone.0191788.ref045">45</xref>]. In STL, MBs act as nuclei in the medium and can induce different effects depending on the acoustic conditions. While MB can be used to induce stable cavitation, which enhance rtPA thrombolysis without disrupting the blood brain barrier [<xref ref-type="bibr" rid="pone.0191788.ref046">46</xref>, <xref ref-type="bibr" rid="pone.0191788.ref047">47</xref>], MB also lower the threshold of inertial cavitation which is able to induce a putative cerebral hemorrhage. Blood brain barrier disruption is induced by STL in certain acoustic conditions, which can also explain ICH (specifically in presence of rtPA, which is known to be neurotoxic and to cause hemorrhage) [<xref ref-type="bibr" rid="pone.0191788.ref044">44</xref>, <xref ref-type="bibr" rid="pone.0191788.ref048">48</xref>, <xref ref-type="bibr" rid="pone.0191788.ref049">49</xref>]. To avoid these adverse effects, some solutions have been developed to create a controlled intracranial US field that have not yet been tested in STL for IS. For example, it is now possible to monitor inertial cavitation in the brain in real time by using a passive cavitation detector [<xref ref-type="bibr" rid="pone.0191788.ref050">50</xref>]. Wright et al. were able to monitor cavitation during sonothrombolysis with high-intensity focused ultrasound in a rabbit femoral artery [<xref ref-type="bibr" rid="pone.0191788.ref051">51</xref>]. Frequency modulation is a solution to lower the occurrence of standing waves [<xref ref-type="bibr" rid="pone.0191788.ref052">52</xref>] through the use of higher US frequencies and short emission duration [<xref ref-type="bibr" rid="pone.0191788.ref044">44</xref>].</p>
<p>Associating STL with thrombolytic drugs or with mechanical thrombi retrieval is not well defined and needs to be fully explored [<xref ref-type="bibr" rid="pone.0191788.ref004">4</xref>]. Similarly, the question of whether STL without thrombolytic drugs or STL with reduced MBs dose leads to better safety ratios in certain clinical situations (e.g., when rtPA is contraindicated) needs to be addressed. Furthermore, the CLOTBUST clinical trial (using US alone) has pointed out that insonation remains operator dependent. A couple of solutions exist—the first one is the MRI-guidance (MRI = Magnetic resonance Imaging) of US [<xref ref-type="bibr" rid="pone.0191788.ref053">53</xref>, <xref ref-type="bibr" rid="pone.0191788.ref054">54</xref>] and, the second one is the use of an operator independent US device (as reported in the CLOTBUST-HF trial) [<xref ref-type="bibr" rid="pone.0191788.ref055">55</xref>]. At this time, none of these solutions have been evaluated with STL in IS.</p>
<p>The use of TMBs seems promising, but TMBs are not yet validated for clinical use even for diagnostic purpose. In addition, regulatory complications that have to be overcome to get clinical approval of a new type of MBs agent will delay the clinical translation of this therapeutic approach. The concentration of MBs to be used is not consensual and appears as a critical safety element. Indeed, Transcranial ultrasound in clinical sonothrombolysis (TUCSON) trial [<xref ref-type="bibr" rid="pone.0191788.ref007">7</xref>] indicate that an association between the concentration of MBs and the rate of cerebral hemorrhage could exist (for the same US parameters). Recently McMahon et al. demonstrated that acute inflammatory response (which lead to microhemorrhage) following blood-brain-barrier opening with focused ultrasound and microbubbles is dependent on microbubble dose [<xref ref-type="bibr" rid="pone.0191788.ref056">56</xref>].</p>
</sec>
<sec id="sec026">
<title>Limitations</title>
<p>The present review represents the first systematic evaluation of in vivo preclinical studies with respect to STL treatment of experimental IS. Although our systematic screening of the relevant databases identified &gt; 1000 articles on STL, only 16 studies met the inclusion criteria. We decide to exclude studies involving coronary or peripheral arteries, as brain has a specific vulnerability to ischemia and hemorrhage that is not present in cardiac muscle or other organs.</p>
<p>We regroup the microthrombi spreading and transient vascular occlusion under the term “microvasculature impairment model”, because authors stated that these models refer to the human “no reflow phenomenon” (where the distal arterioles stay occluded after a large vessel recanalization).</p>
<p>Meta-analysis is not feasible because of the heterogeneity of the studies reviewed.</p>
<p>Our quality evaluation reveals biases, which can be easily corrected in future investigations. 3 studies were published before or the year after the publication of the CAMARADES criteria. The absence of power calculations of the sample sizes in all studies reviewed means that some of the negative results reported may be linked to a default in statistical power. Information such as temperature of the animal is not always monitored, while hypothermia can lead to neuroprotection. Similarly, free neuroprotective anaesthetics can be implemented because their effects can falsely influence treatment outcomes.</p>
</sec>
</sec>
<sec id="sec027" sec-type="conclusions">
<title>Conclusions</title>
<p>STL is a complex treatment requiring a multidisciplinary scientific approach. Nevertheless, selected preclinical studies have shown that STL has a substantial thrombolytic effect. Data available on safety are limited and more preclinical evaluation is needed to demonstrate a clear benefit to risk ratio on clinical endpoints, as compared to approved treatment. We suggest testing frequencies in the range from sub-MHz to 1 MHz, with intensities below the threshold of inertial cavitation, so to favor stable cavitation of microbubbles. The use of frequency modulation and short pulse durations should lessen the probability of the generation of standing wave. While TMB demonstrated a better efficacy than microbubbles, the use of clinically-approved microbubble may accelerate clinical translation. Further investigations on the doses of microbubbles and their association with thrombolytic drugs (mainly rtPA) are needed to improve the therapeutic benefit of STL. Although this therapeutic option could be used for large artery occlusion, this approach should also be beneficial in the situation of microcirculation impairment (e.g., after thrombectomy). Moreover, the future explorations on the safety of STL are essential. To achieve this objective, animal models, which reproduce the human pathophysiology (i.e., older animals, cardio-vascular risk factors, significant duration of ischemia) should be used. Finally, MRI guidance and cavitation detection have not been evaluated in ischemic stroke yet but their use in STL look promising to guarantee a good efficacy/safety profile.</p>
</sec>
<sec id="sec028">
<title>Supporting information</title>
<supplementary-material id="pone.0191788.s001" mimetype="application/msword" position="float" xlink:href="info:doi/10.1371/journal.pone.0191788.s001" xlink:type="simple">
<label>S1 PRISMA Checklist</label>
<caption>
<title>PRISMA checklist of the systematic review following the preferred reporting items for systematic reviews and meta-analyses.</title>
<p>[<xref ref-type="bibr" rid="pone.0191788.ref017">17</xref>].</p>
<p>(DOC)</p>
</caption>
</supplementary-material>
<supplementary-material id="pone.0191788.s002" mimetype="application/vnd.openxmlformats-officedocument.wordprocessingml.document" position="float" xlink:href="info:doi/10.1371/journal.pone.0191788.s002" xlink:type="simple">
<label>S1 File</label>
<caption>
<title>S1 File contains the full electronic search strategy for the two electronical databases.</title>
<p>(DOCX)</p>
</caption>
</supplementary-material>
</sec>
</body>
<back>
<ref-list>
<title>References</title>
<ref id="pone.0191788.ref001"><label>1</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Feigin</surname> <given-names>VL</given-names></name>, <name name-style="western"><surname>Forouzanfar</surname> <given-names>MH</given-names></name>, <name name-style="western"><surname>Krishnamurthi</surname> <given-names>R</given-names></name>, <name name-style="western"><surname>Mensah</surname> <given-names>GA</given-names></name>, <name name-style="western"><surname>Connor</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Bennett</surname> <given-names>DA</given-names></name>, <etal>et al</etal>. <article-title>Global and regional burden of stroke during 1990–2010: findings from the Global Burden of Disease Study 2010</article-title>. <source>Lancet</source>. <year>2014</year>;<volume>383</volume>(<issue>9913</issue>):<fpage>245</fpage>–<lpage>54</lpage>. Epub 2014/01/23. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/S0140-6736(13)61953-4" xlink:type="simple">10.1016/S0140-6736(13)61953-4</ext-link></comment> <object-id pub-id-type="pmid">24449944</object-id>; PubMed Central PMCID: PMCPMC4181600.</mixed-citation></ref>
<ref id="pone.0191788.ref002"><label>2</label><mixed-citation publication-type="journal" xlink:type="simple"><collab>National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group</collab>. <article-title>Tissue plasminogen activator for acute ischemic stroke</article-title>. <source>N Engl J Med</source>. <year>1995</year>;<volume>333</volume>(<issue>24</issue>):<fpage>1581</fpage>–<lpage>7</lpage>. Epub 1995/12/14. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1056/NEJM199512143332401" xlink:type="simple">10.1056/NEJM199512143332401</ext-link></comment> <object-id pub-id-type="pmid">7477192</object-id>.</mixed-citation></ref>
<ref id="pone.0191788.ref003"><label>3</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Campbell</surname> <given-names>BC</given-names></name>, <name name-style="western"><surname>Mitchell</surname> <given-names>PJ</given-names></name>, <name name-style="western"><surname>Kleinig</surname> <given-names>TJ</given-names></name>, <name name-style="western"><surname>Dewey</surname> <given-names>HM</given-names></name>, <name name-style="western"><surname>Churilov</surname> <given-names>L</given-names></name>, <name name-style="western"><surname>Yassi</surname> <given-names>N</given-names></name>, <etal>et al</etal>. <article-title>Endovascular therapy for ischemic stroke with perfusion-imaging selection</article-title>. <source>N Engl J Med</source>. <year>2015</year>;<volume>372</volume>(<issue>11</issue>):<fpage>1009</fpage>–<lpage>18</lpage>. Epub 2015/02/12. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1056/NEJMoa1414792" xlink:type="simple">10.1056/NEJMoa1414792</ext-link></comment> <object-id pub-id-type="pmid">25671797</object-id>.</mixed-citation></ref>
<ref id="pone.0191788.ref004"><label>4</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Berkhemer</surname> <given-names>OA</given-names></name>, <name name-style="western"><surname>Fransen</surname> <given-names>PS</given-names></name>, <name name-style="western"><surname>Beumer</surname> <given-names>D</given-names></name>, <name name-style="western"><surname>van den Berg</surname> <given-names>LA</given-names></name>, <name name-style="western"><surname>Lingsma</surname> <given-names>HF</given-names></name>, <name name-style="western"><surname>Yoo</surname> <given-names>AJ</given-names></name>, <etal>et al</etal>. <article-title>A randomized trial of intraarterial treatment for acute ischemic stroke</article-title>. <source>N Engl J Med</source>. <year>2015</year>;<volume>372</volume>(<issue>1</issue>):<fpage>11</fpage>–<lpage>20</lpage>. Epub 2014/12/18. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1056/NEJMoa1411587" xlink:type="simple">10.1056/NEJMoa1411587</ext-link></comment> <object-id pub-id-type="pmid">25517348</object-id>.</mixed-citation></ref>
<ref id="pone.0191788.ref005"><label>5</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Huang</surname> <given-names>X</given-names></name>, <name name-style="western"><surname>Cheripelli</surname> <given-names>BK</given-names></name>, <name name-style="western"><surname>Lloyd</surname> <given-names>SM</given-names></name>, <name name-style="western"><surname>Kalladka</surname> <given-names>D</given-names></name>, <name name-style="western"><surname>Moreton</surname> <given-names>FC</given-names></name>, <name name-style="western"><surname>Siddiqui</surname> <given-names>A</given-names></name>, <etal>et al</etal>. <article-title>Alteplase versus tenecteplase for thrombolysis after ischaemic stroke (ATTEST): a phase 2, randomised, open-label, blinded endpoint study</article-title>. <source>Lancet Neurol</source>. <year>2015</year>;<volume>14</volume>(<issue>4</issue>):<fpage>368</fpage>–<lpage>76</lpage>. Epub 2015/03/03. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/S1474-4422(15)70017-7" xlink:type="simple">10.1016/S1474-4422(15)70017-7</ext-link></comment> <object-id pub-id-type="pmid">25726502</object-id>.</mixed-citation></ref>
<ref id="pone.0191788.ref006"><label>6</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Larrue</surname> <given-names>V</given-names></name>, <name name-style="western"><surname>Viguier</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Arnaud</surname> <given-names>C</given-names></name>, <name name-style="western"><surname>Cognard</surname> <given-names>C</given-names></name>, <name name-style="western"><surname>Petit</surname> <given-names>R</given-names></name>, <name name-style="western"><surname>Rigal</surname> <given-names>M</given-names></name>, <etal>et al</etal>. <article-title>Transcranial ultrasound combined with intravenous microbubbles and Tissue Plasminogen Activator for Acute Ischemic Stroke: A Randomized Controlled Study</article-title>. <source>Stroke</source>. <year>2007</year>;<volume>38</volume>:<fpage>472</fpage>.</mixed-citation></ref>
<ref id="pone.0191788.ref007"><label>7</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Molina</surname> <given-names>CA</given-names></name>, <name name-style="western"><surname>Barreto</surname> <given-names>AD</given-names></name>, <name name-style="western"><surname>Tsivgoulis</surname> <given-names>G</given-names></name>, <name name-style="western"><surname>Sierzenski</surname> <given-names>P</given-names></name>, <name name-style="western"><surname>Malkoff</surname> <given-names>MD</given-names></name>, <name name-style="western"><surname>Rubiera</surname> <given-names>M</given-names></name>, <etal>et al</etal>. <article-title>Transcranial ultrasound in clinical sonothrombolysis (TUCSON) trial</article-title>. <source>Ann Neurol</source>. <year>2009</year>;<volume>66</volume>(<issue>1</issue>):<fpage>28</fpage>–<lpage>38</lpage>. Epub 2009/08/12. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1002/ana.21723" xlink:type="simple">10.1002/ana.21723</ext-link></comment> <object-id pub-id-type="pmid">19670432</object-id>.</mixed-citation></ref>
<ref id="pone.0191788.ref008"><label>8</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Nacu</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Kvistad</surname> <given-names>CE</given-names></name>, <name name-style="western"><surname>Naess</surname> <given-names>H</given-names></name>, <name name-style="western"><surname>Oygarden</surname> <given-names>H</given-names></name>, <name name-style="western"><surname>Logallo</surname> <given-names>N</given-names></name>, <name name-style="western"><surname>Assmus</surname> <given-names>J</given-names></name>, <etal>et al</etal>. <article-title>NOR-SASS (Norwegian Sonothrombolysis in Acute Stroke Study): Randomized Controlled Contrast-Enhanced Sonothrombolysis in an Unselected Acute Ischemic Stroke Population</article-title>. <source>Stroke</source>. <year>2017</year>;<volume>48</volume>(<issue>2</issue>):<fpage>335</fpage>–<lpage>41</lpage>. Epub 2016/12/17. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1161/STROKEAHA.116.014644" xlink:type="simple">10.1161/STROKEAHA.116.014644</ext-link></comment> <object-id pub-id-type="pmid">27980128</object-id>; PubMed Central PMCID: PMCPMC5266415.</mixed-citation></ref>
<ref id="pone.0191788.ref009"><label>9</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Ricci</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Dinia</surname> <given-names>L</given-names></name>, <name name-style="western"><surname>Del Sette</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Anzola</surname> <given-names>P</given-names></name>, <name name-style="western"><surname>Mazzoli</surname> <given-names>T</given-names></name>, <name name-style="western"><surname>Cenciarelli</surname> <given-names>S</given-names></name>, <etal>et al</etal>. <article-title>Sonothrombolysis for acute ischaemic stroke</article-title>. <source>Cochrane Database Syst Rev</source>. <year>2012</year>;<volume>6</volume>(<issue>6</issue>):<fpage>CD008348</fpage>. Epub 2012/06/15. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1002/14651858.CD008348.pub2" xlink:type="simple">10.1002/14651858.CD008348.pub2</ext-link></comment> <object-id pub-id-type="pmid">22696378</object-id>.</mixed-citation></ref>
<ref id="pone.0191788.ref010"><label>10</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Saqqur</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Tsivgoulis</surname> <given-names>G</given-names></name>, <name name-style="western"><surname>Nicoli</surname> <given-names>F</given-names></name>, <name name-style="western"><surname>Skoloudik</surname> <given-names>D</given-names></name>, <name name-style="western"><surname>Sharma</surname> <given-names>VK</given-names></name>, <name name-style="western"><surname>Larrue</surname> <given-names>V</given-names></name>, <etal>et al</etal>. <article-title>The role of sonolysis and sonothrombolysis in acute ischemic stroke: a systematic review and meta-analysis of randomized controlled trials and case-control studies</article-title>. <source>J Neuroimaging</source>. <year>2014</year>;<volume>24</volume>(<issue>3</issue>):<fpage>209</fpage>–<lpage>20</lpage>. Epub 2013/04/24. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1111/jon.12026" xlink:type="simple">10.1111/jon.12026</ext-link></comment> <object-id pub-id-type="pmid">23607713</object-id>.</mixed-citation></ref>
<ref id="pone.0191788.ref011"><label>11</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Tachibana</surname> <given-names>K</given-names></name>, <name name-style="western"><surname>Tachibana</surname> <given-names>S</given-names></name>. <article-title>Albumin microbubble echo-contrast material as an enhancer for ultrasound accelerated thrombolysis</article-title>. <source>Circulation</source>. <year>1995</year>;<volume>92</volume>(<issue>5</issue>):<fpage>1148</fpage>–<lpage>50</lpage>. Epub 1995/09/01. <object-id pub-id-type="pmid">7648659</object-id>.</mixed-citation></ref>
<ref id="pone.0191788.ref012"><label>12</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Meairs</surname> <given-names>S</given-names></name>. <article-title>Contrast-enhanced ultrasound perfusion imaging in acute stroke patients</article-title>. <source>Eur Neurol</source>. <year>2008</year>;<volume>59</volume> <issue>Suppl 1</issue>:<fpage>17</fpage>–<lpage>26</lpage>. Epub 2008/04/18. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1159/000114456" xlink:type="simple">10.1159/000114456</ext-link></comment> <object-id pub-id-type="pmid">18382109</object-id>.</mixed-citation></ref>
<ref id="pone.0191788.ref013"><label>13</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Meairs</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Alonso</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Hennerici</surname> <given-names>MG</given-names></name>. <article-title>Progress in sonothrombolysis for the treatment of stroke</article-title>. <source>Stroke</source>. <year>2012</year>;<volume>43</volume>(<issue>6</issue>):<fpage>1706</fpage>–<lpage>10</lpage>. Epub 2012/04/27. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1161/STROKEAHA.111.636332" xlink:type="simple">10.1161/STROKEAHA.111.636332</ext-link></comment> <object-id pub-id-type="pmid">22535275</object-id>.</mixed-citation></ref>
<ref id="pone.0191788.ref014"><label>14</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Bader</surname> <given-names>KB</given-names></name>, <name name-style="western"><surname>Bouchoux</surname> <given-names>G</given-names></name>, <name name-style="western"><surname>Holland</surname> <given-names>CK</given-names></name>. <article-title>Sonothrombolysis</article-title>. In: <name name-style="western"><surname>Escoffre</surname> <given-names>JM</given-names></name>, <name name-style="western"><surname>Bouakaz</surname> <given-names>A</given-names></name>, editors. <source>Therapeutic Ultrasound</source><year>2016</year>. p. <fpage>339</fpage>–<lpage>62</lpage>.</mixed-citation></ref>
<ref id="pone.0191788.ref015"><label>15</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Stride</surname> <given-names>E</given-names></name>. <article-title>Physical Principles of Microbubbles for Ultrasound Imaging and Therapy</article-title>. In: <name name-style="western"><surname>Alonso</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Hennerici</surname> <given-names>MG</given-names></name>, <name name-style="western"><surname>Meairs</surname> <given-names>S</given-names></name>, editors. <source>Translational Neurosonology</source><year>2015</year>. p. <fpage>11</fpage>–<lpage>22</lpage>.</mixed-citation></ref>
<ref id="pone.0191788.ref016"><label>16</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Sena</surname> <given-names>E</given-names></name>, <name name-style="western"><surname>van der Worp</surname> <given-names>HB</given-names></name>, <name name-style="western"><surname>Howells</surname> <given-names>D</given-names></name>, <name name-style="western"><surname>Macleod</surname> <given-names>M</given-names></name>. <article-title>How can we improve the pre-clinical development of drugs for stroke?</article-title> <source>Trends Neurosci</source>. <year>2007</year>;<volume>30</volume>(<issue>9</issue>):<fpage>433</fpage>–<lpage>9</lpage>. Epub 2007/09/04. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.tins.2007.06.009" xlink:type="simple">10.1016/j.tins.2007.06.009</ext-link></comment> <object-id pub-id-type="pmid">17765332</object-id>.</mixed-citation></ref>
<ref id="pone.0191788.ref017"><label>17</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Moher</surname> <given-names>D</given-names></name>, <name name-style="western"><surname>Liberati</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Tetzlaff</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Altman</surname> <given-names>DG</given-names></name>, <name name-style="western"><surname>Group</surname> <given-names>P</given-names></name>. <article-title>Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement</article-title>. <source>J Clin Epidemiol</source>. <year>2009</year>;<volume>62</volume>(<issue>10</issue>):<fpage>1006</fpage>–<lpage>12</lpage>. Epub 2009/07/28. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.jclinepi.2009.06.005" xlink:type="simple">10.1016/j.jclinepi.2009.06.005</ext-link></comment> <object-id pub-id-type="pmid">19631508</object-id>.</mixed-citation></ref>
<ref id="pone.0191788.ref018"><label>18</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Culp</surname> <given-names>WC</given-names></name>, <name name-style="western"><surname>Erdem</surname> <given-names>E</given-names></name>, <name name-style="western"><surname>Roberson</surname> <given-names>PK</given-names></name>, <name name-style="western"><surname>Husain</surname> <given-names>MM</given-names></name>. <article-title>Microbubble potentiated ultrasound as a method of stroke therapy in a pig model: preliminary findings</article-title>. <source>J Vasc Interv Radiol</source>. <year>2003</year>;<volume>14</volume>(<issue>11</issue>):<fpage>1433</fpage>–<lpage>6</lpage>. Epub 2003/11/08. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1097/01.RVI.0000096767.47047.FA" xlink:type="simple">10.1097/01.RVI.0000096767.47047.FA</ext-link></comment> <object-id pub-id-type="pmid">14605109</object-id>.</mixed-citation></ref>
<ref id="pone.0191788.ref019"><label>19</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Culp</surname> <given-names>WC</given-names></name>, <name name-style="western"><surname>Porter</surname> <given-names>TR</given-names></name>, <name name-style="western"><surname>Lowery</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Xie</surname> <given-names>F</given-names></name>, <name name-style="western"><surname>Roberson</surname> <given-names>PK</given-names></name>, <name name-style="western"><surname>Marky</surname> <given-names>L</given-names></name>. <article-title>Intracranial clot lysis with intravenous microbubbles and transcranial ultrasound in swine</article-title>. <source>Stroke</source>. <year>2004</year>;<volume>35</volume>(<issue>10</issue>):<fpage>2407</fpage>–<lpage>11</lpage>. Epub 2004/08/24. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1161/01.STR.0000140890.86779.79" xlink:type="simple">10.1161/01.STR.0000140890.86779.79</ext-link></comment> <object-id pub-id-type="pmid">15322299</object-id>.</mixed-citation></ref>
<ref id="pone.0191788.ref020"><label>20</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Gao</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Zhang</surname> <given-names>Y</given-names></name>, <name name-style="western"><surname>Wu</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Shi</surname> <given-names>WT</given-names></name>, <name name-style="western"><surname>Lof</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Vignon</surname> <given-names>F</given-names></name>, <etal>et al</etal>. <article-title>Improvements in cerebral blood flow and recanalization rates with transcranial diagnostic ultrasound and intravenous microbubbles after acute cerebral emboli</article-title>. <source>Invest Radiol</source>. <year>2014</year>;<volume>49</volume>(<issue>9</issue>):<fpage>593</fpage>–<lpage>600</lpage>. Epub 2014/04/03. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1097/RLI.0000000000000059" xlink:type="simple">10.1097/RLI.0000000000000059</ext-link></comment> <object-id pub-id-type="pmid">24691139</object-id>.</mixed-citation></ref>
<ref id="pone.0191788.ref021"><label>21</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Brown</surname> <given-names>AT</given-names></name>, <name name-style="western"><surname>Flores</surname> <given-names>R</given-names></name>, <name name-style="western"><surname>Hamilton</surname> <given-names>E</given-names></name>, <name name-style="western"><surname>Roberson</surname> <given-names>PK</given-names></name>, <name name-style="western"><surname>Borrelli</surname> <given-names>MJ</given-names></name>, <name name-style="western"><surname>Culp</surname> <given-names>WC</given-names></name>. <article-title>Microbubbles improve sonothrombolysis in vitro and decrease hemorrhage in vivo in a rabbit stroke model</article-title>. <source>Invest Radiol</source>. <year>2011</year>;<volume>46</volume>(<issue>3</issue>):<fpage>202</fpage>–<lpage>7</lpage>. Epub 2010/12/15. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1097/RLI.0b013e318200757a" xlink:type="simple">10.1097/RLI.0b013e318200757a</ext-link></comment> <object-id pub-id-type="pmid">21150788</object-id>; PubMed Central PMCID: PMCPMC3845811.</mixed-citation></ref>
<ref id="pone.0191788.ref022"><label>22</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Culp</surname> <given-names>WC</given-names></name>, <name name-style="western"><surname>Flores</surname> <given-names>R</given-names></name>, <name name-style="western"><surname>Brown</surname> <given-names>AT</given-names></name>, <name name-style="western"><surname>Lowery</surname> <given-names>JD</given-names></name>, <name name-style="western"><surname>Roberson</surname> <given-names>PK</given-names></name>, <name name-style="western"><surname>Hennings</surname> <given-names>LJ</given-names></name>, <etal>et al</etal>. <article-title>Successful microbubble sonothrombolysis without tissue-type plasminogen activator in a rabbit model of acute ischemic stroke</article-title>. <source>Stroke</source>. <year>2011</year>;<volume>42</volume>(<issue>8</issue>):<fpage>2280</fpage>–<lpage>5</lpage>. Epub 2011/06/28. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1161/STROKEAHA.110.607150" xlink:type="simple">10.1161/STROKEAHA.110.607150</ext-link></comment> <object-id pub-id-type="pmid">21700942</object-id>; PubMed Central PMCID: PMCPMC3266124.</mixed-citation></ref>
<ref id="pone.0191788.ref023"><label>23</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Flores</surname> <given-names>R</given-names></name>, <name name-style="western"><surname>Hennings</surname> <given-names>LJ</given-names></name>, <name name-style="western"><surname>Lowery</surname> <given-names>JD</given-names></name>, <name name-style="western"><surname>Brown</surname> <given-names>AT</given-names></name>, <name name-style="western"><surname>Culp</surname> <given-names>WC</given-names></name>. <article-title>Microbubble-augmented ultrasound sonothrombolysis decreases intracranial hemorrhage in a rabbit model of acute ischemic stroke</article-title>. <source>Invest Radiol</source>. <year>2011</year>;<volume>46</volume>(<issue>7</issue>):<fpage>419</fpage>–<lpage>24</lpage>. Epub 2011/02/24. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1097/RLI.0b013e31820e143a" xlink:type="simple">10.1097/RLI.0b013e31820e143a</ext-link></comment> <object-id pub-id-type="pmid">21343824</object-id>; PubMed Central PMCID: PMCPMC3109116.</mixed-citation></ref>
<ref id="pone.0191788.ref024"><label>24</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Liu</surname> <given-names>WS</given-names></name>, <name name-style="western"><surname>Huang</surname> <given-names>ZZ</given-names></name>, <name name-style="western"><surname>Wang</surname> <given-names>XW</given-names></name>, <name name-style="western"><surname>Zhou</surname> <given-names>J</given-names></name>. <article-title>Effects of microbubbles on transcranial Doppler ultrasound-assisted intracranial urokinase thrombolysis</article-title>. <source>Thromb Res</source>. <year>2012</year>;<volume>130</volume>(<issue>3</issue>):<fpage>547</fpage>–<lpage>51</lpage>. Epub 2012/07/25. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.thromres.2012.06.020" xlink:type="simple">10.1016/j.thromres.2012.06.020</ext-link></comment> <object-id pub-id-type="pmid">22823944</object-id>.</mixed-citation></ref>
<ref id="pone.0191788.ref025"><label>25</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Ren</surname> <given-names>ST</given-names></name>, <name name-style="western"><surname>Long</surname> <given-names>LH</given-names></name>, <name name-style="western"><surname>Wang</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Li</surname> <given-names>YP</given-names></name>, <name name-style="western"><surname>Qin</surname> <given-names>H</given-names></name>, <name name-style="western"><surname>Zhang</surname> <given-names>H</given-names></name>, <etal>et al</etal>. <article-title>Thrombolytic effects of a combined therapy with targeted microbubbles and ultrasound in a 6 h cerebral thrombosis rabbit model</article-title>. <source>J Thromb Thrombolysis</source>. <year>2012</year>;<volume>33</volume>(<issue>1</issue>):<fpage>74</fpage>–<lpage>81</lpage>. Epub 2011/10/22. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1007/s11239-011-0644-z" xlink:type="simple">10.1007/s11239-011-0644-z</ext-link></comment> <object-id pub-id-type="pmid">22016106</object-id>.</mixed-citation></ref>
<ref id="pone.0191788.ref026"><label>26</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Wang</surname> <given-names>B</given-names></name>, <name name-style="western"><surname>Wang</surname> <given-names>L</given-names></name>, <name name-style="western"><surname>Zhou</surname> <given-names>XB</given-names></name>, <name name-style="western"><surname>Liu</surname> <given-names>YM</given-names></name>, <name name-style="western"><surname>Wang</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Qin</surname> <given-names>H</given-names></name>, <etal>et al</etal>. <article-title>Thrombolysis effect of a novel targeted microbubble with low-frequency ultrasound in vivo</article-title>. <source>Thromb Haemost</source>. <year>2008</year>;<volume>100</volume>(<issue>2</issue>):<fpage>356</fpage>–<lpage>61</lpage>. Epub 2008/08/12. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1160/TH07-09-0583" xlink:type="simple">10.1160/TH07-09-0583</ext-link></comment> <object-id pub-id-type="pmid">18690359</object-id>.</mixed-citation></ref>
<ref id="pone.0191788.ref027"><label>27</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Alonso</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Dempfle</surname> <given-names>CE</given-names></name>, <name name-style="western"><surname>Della Martina</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Stroick</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Fatar</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Zohsel</surname> <given-names>K</given-names></name>, <etal>et al</etal>. <article-title>In vivo clot lysis of human thrombus with intravenous abciximab immunobubbles and ultrasound</article-title>. <source>Thromb Res</source>. <year>2009</year>;<volume>124</volume>(<issue>1</issue>):<fpage>70</fpage>–<lpage>4</lpage>. Epub 2009/04/08. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.thromres.2008.11.019" xlink:type="simple">10.1016/j.thromres.2008.11.019</ext-link></comment> <object-id pub-id-type="pmid">19349068</object-id>.</mixed-citation></ref>
<ref id="pone.0191788.ref028"><label>28</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Lu</surname> <given-names>Y</given-names></name>, <name name-style="western"><surname>Wang</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Huang</surname> <given-names>R</given-names></name>, <name name-style="western"><surname>Chen</surname> <given-names>G</given-names></name>, <name name-style="western"><surname>Zhong</surname> <given-names>L</given-names></name>, <name name-style="western"><surname>Shen</surname> <given-names>S</given-names></name>, <etal>et al</etal>. <article-title>Microbubble-Mediated Sonothrombolysis Improves Outcome After Thrombotic Microembolism-Induced Acute Ischemic Stroke</article-title>. <source>Stroke</source>. <year>2016</year>;<volume>47</volume>(<issue>5</issue>):<fpage>1344</fpage>–<lpage>53</lpage>. Epub 2016/04/07. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1161/STROKEAHA.115.012056" xlink:type="simple">10.1161/STROKEAHA.115.012056</ext-link></comment> <object-id pub-id-type="pmid">27048701</object-id>.</mixed-citation></ref>
<ref id="pone.0191788.ref029"><label>29</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Moumouh</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Barentin</surname> <given-names>L</given-names></name>, <name name-style="western"><surname>Tranquart</surname> <given-names>F</given-names></name>, <name name-style="western"><surname>Serrierre</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Bonnaud</surname> <given-names>I</given-names></name>, <name name-style="western"><surname>Tasu</surname> <given-names>JP</given-names></name>. <article-title>Fibrinolytic effects of transparietal ultrasound associated with intravenous infusion of an ultrasound contrast agent: study of a rat model of acute cerebral stroke</article-title>. <source>Ultrasound Med Biol</source>. <year>2010</year>;<volume>36</volume>(<issue>1</issue>):<fpage>51</fpage>–<lpage>7</lpage>. Epub 2009/10/27. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.ultrasmedbio.2009.06.1103" xlink:type="simple">10.1016/j.ultrasmedbio.2009.06.1103</ext-link></comment> <object-id pub-id-type="pmid">19854567</object-id>.</mixed-citation></ref>
<ref id="pone.0191788.ref030"><label>30</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Ren</surname> <given-names>X</given-names></name>, <name name-style="western"><surname>Wang</surname> <given-names>Y</given-names></name>, <name name-style="western"><surname>Wang</surname> <given-names>Y</given-names></name>, <name name-style="western"><surname>Chen</surname> <given-names>H</given-names></name>, <name name-style="western"><surname>Chen</surname> <given-names>L</given-names></name>, <name name-style="western"><surname>Liu</surname> <given-names>Y</given-names></name>, <etal>et al</etal>. <article-title>Thrombolytic therapy with rt-PA and transcranial color Doppler ultrasound (TCCS) combined with microbubbles for embolic thrombus</article-title>. <source>Thromb Res</source>. <year>2015</year>;<volume>136</volume>(<issue>5</issue>):<fpage>1027</fpage>–<lpage>32</lpage>. Epub 2015/09/22. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.thromres.2015.08.027" xlink:type="simple">10.1016/j.thromres.2015.08.027</ext-link></comment> <object-id pub-id-type="pmid">26388121</object-id>.</mixed-citation></ref>
<ref id="pone.0191788.ref031"><label>31</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Tomkins</surname> <given-names>AJ</given-names></name>, <name name-style="western"><surname>Schleicher</surname> <given-names>N</given-names></name>, <name name-style="western"><surname>Murtha</surname> <given-names>L</given-names></name>, <name name-style="western"><surname>Kaps</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Levi</surname> <given-names>CR</given-names></name>, <name name-style="western"><surname>Nedelmann</surname> <given-names>M</given-names></name>, <etal>et al</etal>. <article-title>Platelet rich clots are resistant to lysis by thrombolytic therapy in a rat model of embolic stroke</article-title>. <source>Exp Transl Stroke Med</source>. <year>2015</year>;<volume>7</volume>:<fpage>2</fpage>. Epub 2015/02/07. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1186/s13231-014-0014-y" xlink:type="simple">10.1186/s13231-014-0014-y</ext-link></comment> <object-id pub-id-type="pmid">25657829</object-id>; PubMed Central PMCID: PMCPMC4318170.</mixed-citation></ref>
<ref id="pone.0191788.ref032"><label>32</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Nedelmann</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Ritschel</surname> <given-names>N</given-names></name>, <name name-style="western"><surname>Doenges</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Langheinrich</surname> <given-names>AC</given-names></name>, <name name-style="western"><surname>Acker</surname> <given-names>T</given-names></name>, <name name-style="western"><surname>Reuter</surname> <given-names>P</given-names></name>, <etal>et al</etal>. <article-title>Combined contrast-enhanced ultrasound and rt-PA treatment is safe and improves impaired microcirculation after reperfusion of middle cerebral artery occlusion</article-title>. <source>J Cereb Blood Flow Metab</source>. <year>2010</year>;<volume>30</volume>(<issue>10</issue>):<fpage>1712</fpage>–<lpage>20</lpage>. Epub 2010/06/10. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1038/jcbfm.2010.82" xlink:type="simple">10.1038/jcbfm.2010.82</ext-link></comment> <object-id pub-id-type="pmid">20531462</object-id>; PubMed Central PMCID: PMCPMC3023400.</mixed-citation></ref>
<ref id="pone.0191788.ref033"><label>33</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Schleicher</surname> <given-names>N</given-names></name>, <name name-style="western"><surname>Tomkins</surname> <given-names>AJ</given-names></name>, <name name-style="western"><surname>Kampschulte</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Hyvelin</surname> <given-names>JM</given-names></name>, <name name-style="western"><surname>Botteron</surname> <given-names>C</given-names></name>, <name name-style="western"><surname>Juenemann</surname> <given-names>M</given-names></name>, <etal>et al</etal>. <article-title>Sonothrombolysis with BR38 Microbubbles Improves Microvascular Patency in a Rat Model of Stroke</article-title>. <source>PLoS One</source>. <year>2016</year>;<volume>11</volume>(<issue>4</issue>):<fpage>e0152898</fpage>. Epub 2016/04/15. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1371/journal.pone.0152898" xlink:type="simple">10.1371/journal.pone.0152898</ext-link></comment> <object-id pub-id-type="pmid">27077372</object-id>; PubMed Central PMCID: PMCPMC4831751.</mixed-citation></ref>
<ref id="pone.0191788.ref034"><label>34</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Woods</surname> <given-names>SD</given-names></name>, <name name-style="western"><surname>Flores</surname> <given-names>R</given-names></name>, <name name-style="western"><surname>Roberson</surname> <given-names>PK</given-names></name>, <name name-style="western"><surname>Lowery</surname> <given-names>JD</given-names></name>, <name name-style="western"><surname>Skinner</surname> <given-names>RD</given-names></name>, <name name-style="western"><surname>Culp</surname> <given-names>WC</given-names></name>. <article-title>Decreased Serum Levels of S-100B Protein Reflect Successful Treatment Effects in a Rabbit Model of Acute Ischemic Stroke</article-title>. <source>Open Neurol J</source>. <year>2011</year>;<volume>5</volume>:<fpage>55</fpage>–<lpage>7</lpage>. Epub 2011/07/16. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.2174/1874205X01105010055" xlink:type="simple">10.2174/1874205X01105010055</ext-link></comment> <object-id pub-id-type="pmid">21760859</object-id>; PubMed Central PMCID: PMCPMC3134987.</mixed-citation></ref>
<ref id="pone.0191788.ref035"><label>35</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Alexandrov</surname> <given-names>AV</given-names></name>, <name name-style="western"><surname>Demchuk</surname> <given-names>AM</given-names></name>, <name name-style="western"><surname>Burgin</surname> <given-names>WS</given-names></name>, <name name-style="western"><surname>Robinson</surname> <given-names>DJ</given-names></name>, <name name-style="western"><surname>Grotta</surname> <given-names>JC</given-names></name>, <name name-style="western"><surname>Investigators</surname> <given-names>C</given-names></name>. <article-title>Ultrasound-enhanced thrombolysis for acute ischemic stroke: phase I. Findings of the CLOTBUST trial</article-title>. <source>J Neuroimaging</source>. <year>2004</year>;<volume>14</volume>(<issue>2</issue>):<fpage>113</fpage>–<lpage>7</lpage>. Epub 2004/04/21. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1177/1051228403261462" xlink:type="simple">10.1177/1051228403261462</ext-link></comment> <object-id pub-id-type="pmid">15095555</object-id>.</mixed-citation></ref>
<ref id="pone.0191788.ref036"><label>36</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Fisher</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Feuerstein</surname> <given-names>G</given-names></name>, <name name-style="western"><surname>Howells</surname> <given-names>DW</given-names></name>, <name name-style="western"><surname>Hurn</surname> <given-names>PD</given-names></name>, <name name-style="western"><surname>Kent</surname> <given-names>TA</given-names></name>, <name name-style="western"><surname>Savitz</surname> <given-names>SI</given-names></name>, <etal>et al</etal>. <article-title>Update of the stroke therapy academic industry roundtable preclinical recommendations</article-title>. <source>Stroke</source>. <year>2009</year>;<volume>40</volume>(<issue>6</issue>):<fpage>2244</fpage>–<lpage>50</lpage>. Epub 2009/02/28. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1161/STROKEAHA.108.541128" xlink:type="simple">10.1161/STROKEAHA.108.541128</ext-link></comment> <object-id pub-id-type="pmid">19246690</object-id>; PubMed Central PMCID: PMCPMC2888275.</mixed-citation></ref>
<ref id="pone.0191788.ref037"><label>37</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Fisher</surname> <given-names>M</given-names></name>. <article-title>The ischemic penumbra: identification, evolution and treatment concepts</article-title>. <source>Cerebrovasc Dis</source>. <year>2004</year>;<volume>17</volume> <issue>Suppl 1</issue>:<fpage>1</fpage>–<lpage>6</lpage>. Epub 2003/12/25. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1159/000074790" xlink:type="simple">10.1159/000074790</ext-link></comment> <object-id pub-id-type="pmid">14694275</object-id>.</mixed-citation></ref>
<ref id="pone.0191788.ref038"><label>38</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Pan</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Konstas</surname> <given-names>AA</given-names></name>, <name name-style="western"><surname>Bateman</surname> <given-names>B</given-names></name>, <name name-style="western"><surname>Ortolano</surname> <given-names>GA</given-names></name>, <name name-style="western"><surname>Pile-Spellman</surname> <given-names>J</given-names></name>. <article-title>Reperfusion injury following cerebral ischemia: pathophysiology, MR imaging, and potential therapies</article-title>. <source>Neuroradiology</source>. <year>2007</year>;<volume>49</volume>(<issue>2</issue>):<fpage>93</fpage>–<lpage>102</lpage>. Epub 2006/12/21. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1007/s00234-006-0183-z" xlink:type="simple">10.1007/s00234-006-0183-z</ext-link></comment> <object-id pub-id-type="pmid">17177065</object-id>; PubMed Central PMCID: PMCPMC1786189.</mixed-citation></ref>
<ref id="pone.0191788.ref039"><label>39</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Wang</surname> <given-names>Q</given-names></name>, <name name-style="western"><surname>Tang</surname> <given-names>XN</given-names></name>, <name name-style="western"><surname>Yenari</surname> <given-names>MA</given-names></name>. <article-title>The inflammatory response in stroke</article-title>. <source>J Neuroimmunol</source>. <year>2007</year>;<volume>184</volume>(<issue>1–2</issue>):<fpage>53</fpage>–<lpage>68</lpage>. Epub 2006/12/26. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.jneuroim.2006.11.014" xlink:type="simple">10.1016/j.jneuroim.2006.11.014</ext-link></comment> <object-id pub-id-type="pmid">17188755</object-id>; PubMed Central PMCID: PMCPMC1868538.</mixed-citation></ref>
<ref id="pone.0191788.ref040"><label>40</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>O'Reilly</surname> <given-names>MA</given-names></name>, <name name-style="western"><surname>Huang</surname> <given-names>Y</given-names></name>, <name name-style="western"><surname>Hynynen</surname> <given-names>K</given-names></name>. <article-title>The impact of standing wave effects on transcranial focused ultrasound disruption of the blood-brain barrier in a rat model</article-title>. <source>Phys Med Biol</source>. <year>2010</year>;<volume>55</volume>(<issue>18</issue>):<fpage>5251</fpage>–<lpage>67</lpage>. Epub 2010/08/20. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1088/0031-9155/55/18/001" xlink:type="simple">10.1088/0031-9155/55/18/001</ext-link></comment> <object-id pub-id-type="pmid">20720286</object-id>; PubMed Central PMCID: PMCPMC3207361.</mixed-citation></ref>
<ref id="pone.0191788.ref041"><label>41</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Daffertshofer</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Gass</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Ringleb</surname> <given-names>P</given-names></name>, <name name-style="western"><surname>Sitzer</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Sliwka</surname> <given-names>U</given-names></name>, <name name-style="western"><surname>Els</surname> <given-names>T</given-names></name>, <etal>et al</etal>. <article-title>Transcranial low-frequency ultrasound-mediated thrombolysis in brain ischemia: increased risk of hemorrhage with combined ultrasound and tissue plasminogen activator: results of a phase II clinical trial</article-title>. <source>Stroke</source>. <year>2005</year>;<volume>36</volume>(<issue>7</issue>):<fpage>1441</fpage>–<lpage>6</lpage>. Epub 2005/06/11. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1161/01.STR.0000170707.86793.1a" xlink:type="simple">10.1161/01.STR.0000170707.86793.1a</ext-link></comment> <object-id pub-id-type="pmid">15947262</object-id>.</mixed-citation></ref>
<ref id="pone.0191788.ref042"><label>42</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Adams</surname> <given-names>HP, Jr.</given-names></name>, <name name-style="western"><surname>Bendixen</surname> <given-names>BH</given-names></name>, <name name-style="western"><surname>Kappelle</surname> <given-names>LJ</given-names></name>, <name name-style="western"><surname>Biller</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Love</surname> <given-names>BB</given-names></name>, <name name-style="western"><surname>Gordon</surname> <given-names>DL</given-names></name>, <etal>et al</etal>. <article-title>Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment</article-title>. <source>Stroke</source>. <year>1993</year>;<volume>24</volume>(<issue>1</issue>):<fpage>35</fpage>–<lpage>41</lpage>. Epub 1993/01/01. <object-id pub-id-type="pmid">7678184</object-id>.</mixed-citation></ref>
<ref id="pone.0191788.ref043"><label>43</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Ammi</surname> <given-names>AY</given-names></name>, <name name-style="western"><surname>Mast</surname> <given-names>TD</given-names></name>, <name name-style="western"><surname>Huang</surname> <given-names>IH</given-names></name>, <name name-style="western"><surname>Abruzzo</surname> <given-names>TA</given-names></name>, <name name-style="western"><surname>Coussios</surname> <given-names>CC</given-names></name>, <name name-style="western"><surname>Shaw</surname> <given-names>GJ</given-names></name>, <etal>et al</etal>. <article-title>Characterization of ultrasound propagation through ex-vivo human temporal bone</article-title>. <source>Ultrasound Med Biol</source>. <year>2008</year>;<volume>34</volume>(<issue>10</issue>):<fpage>1578</fpage>–<lpage>89</lpage>. Epub 2008/05/06. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.ultrasmedbio.2008.02.012" xlink:type="simple">10.1016/j.ultrasmedbio.2008.02.012</ext-link></comment> <object-id pub-id-type="pmid">18456391</object-id>; PubMed Central PMCID: PMCPMC4921610.</mixed-citation></ref>
<ref id="pone.0191788.ref044"><label>44</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Baron</surname> <given-names>C</given-names></name>, <name name-style="western"><surname>Aubry</surname> <given-names>JF</given-names></name>, <name name-style="western"><surname>Tanter</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Meairs</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Fink</surname> <given-names>M</given-names></name>. <article-title>Simulation of intracranial acoustic fields in clinical trials of sonothrombolysis</article-title>. <source>Ultrasound Med Biol</source>. <year>2009</year>;<volume>35</volume>(<issue>7</issue>):<fpage>1148</fpage>–<lpage>58</lpage>. Epub 2009/04/28. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.ultrasmedbio.2008.11.014" xlink:type="simple">10.1016/j.ultrasmedbio.2008.11.014</ext-link></comment> <object-id pub-id-type="pmid">19394756</object-id>.</mixed-citation></ref>
<ref id="pone.0191788.ref045"><label>45</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Azuma</surname> <given-names>T</given-names></name>, <name name-style="western"><surname>Kawabata</surname> <given-names>K-i</given-names></name>, <name name-style="western"><surname>Umemura</surname> <given-names>S-i</given-names></name>, <name name-style="western"><surname>Ogihara</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Kubota</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Sasaki</surname> <given-names>A</given-names></name>, <etal>et al</etal>. <article-title>Bubble Generation by Standing Wave in Water Surrounded by Cranium with Transcranial Ultrasonic Beam</article-title>. <source>Jpn J Appl Phys</source>. <year>2005</year>;<volume>44</volume>(<issue>6B</issue>):<fpage>4625</fpage>–<lpage>30</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1143/jjap.44.4625" xlink:type="simple">10.1143/jjap.44.4625</ext-link></comment></mixed-citation></ref>
<ref id="pone.0191788.ref046"><label>46</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Bader</surname> <given-names>KB</given-names></name>, <name name-style="western"><surname>Gruber</surname> <given-names>MJ</given-names></name>, <name name-style="western"><surname>Holland</surname> <given-names>CK</given-names></name>. <article-title>Shaken and stirred: mechanisms of ultrasound-enhanced thrombolysis</article-title>. <source>Ultrasound Med Biol</source>. <year>2015</year>;<volume>41</volume>(<issue>1</issue>):<fpage>187</fpage>–<lpage>96</lpage>. Epub 2014/12/03. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.ultrasmedbio.2014.08.018" xlink:type="simple">10.1016/j.ultrasmedbio.2014.08.018</ext-link></comment> <object-id pub-id-type="pmid">25438846</object-id>; PubMed Central PMCID: PMCPMC4258471.</mixed-citation></ref>
<ref id="pone.0191788.ref047"><label>47</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>O'Reilly</surname> <given-names>MA</given-names></name>, <name name-style="western"><surname>Hynynen</surname> <given-names>K</given-names></name>. <article-title>Blood-brain barrier: real-time feedback-controlled focused ultrasound disruption by using an acoustic emissions-based controller</article-title>. <source>Radiology</source>. <year>2012</year>;<volume>263</volume>(<issue>1</issue>):<fpage>96</fpage>–<lpage>106</lpage>. Epub 2012/02/15. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1148/radiol.11111417" xlink:type="simple">10.1148/radiol.11111417</ext-link></comment> <object-id pub-id-type="pmid">22332065</object-id>; PubMed Central PMCID: PMCPMC3309801.</mixed-citation></ref>
<ref id="pone.0191788.ref048"><label>48</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Kaur</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Zhao</surname> <given-names>Z</given-names></name>, <name name-style="western"><surname>Klein</surname> <given-names>GM</given-names></name>, <name name-style="western"><surname>Lo</surname> <given-names>EH</given-names></name>, <name name-style="western"><surname>Buchan</surname> <given-names>AM</given-names></name>. <article-title>The neurotoxicity of tissue plasminogen activator?</article-title> <source>J Cereb Blood Flow Metab</source>. <year>2004</year>;<volume>24</volume>(<issue>9</issue>):<fpage>945</fpage>–<lpage>63</lpage>. Epub 2004/09/10. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1097/01.WCB.0000137868.50767.E8" xlink:type="simple">10.1097/01.WCB.0000137868.50767.E8</ext-link></comment> <object-id pub-id-type="pmid">15356416</object-id>.</mixed-citation></ref>
<ref id="pone.0191788.ref049"><label>49</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Benchenane</surname> <given-names>K</given-names></name>, <name name-style="western"><surname>Lopez-Atalaya</surname> <given-names>JP</given-names></name>, <name name-style="western"><surname>Fernandez-Monreal</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Touzani</surname> <given-names>O</given-names></name>, <name name-style="western"><surname>Vivien</surname> <given-names>D</given-names></name>. <article-title>Equivocal roles of tissue-type plasminogen activator in stroke-induced injury</article-title>. <source>Trends Neurosci</source>. <year>2004</year>;<volume>27</volume>(<issue>3</issue>):<fpage>155</fpage>–<lpage>60</lpage>. Epub 2004/03/24. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.tins.2003.12.011" xlink:type="simple">10.1016/j.tins.2003.12.011</ext-link></comment> <object-id pub-id-type="pmid">15036881</object-id>.</mixed-citation></ref>
<ref id="pone.0191788.ref050"><label>50</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Wu</surname> <given-names>SY</given-names></name>, <name name-style="western"><surname>Tung</surname> <given-names>YS</given-names></name>, <name name-style="western"><surname>Marquet</surname> <given-names>F</given-names></name>, <name name-style="western"><surname>Downs</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Sanchez</surname> <given-names>C</given-names></name>, <name name-style="western"><surname>Chen</surname> <given-names>C</given-names></name>, <etal>et al</etal>. <article-title>Transcranial cavitation detection in primates during blood-brain barrier opening—a performance assessment study</article-title>. <source>IEEE Trans Ultrason Ferroelectr Freq Control</source>. <year>2014</year>;<volume>61</volume>(<issue>6</issue>):<fpage>966</fpage>–<lpage>78</lpage>. Epub 2014/05/27. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1109/TUFFC.2014.2992" xlink:type="simple">10.1109/TUFFC.2014.2992</ext-link></comment> <object-id pub-id-type="pmid">24859660</object-id>; PubMed Central PMCID: PMCPMC4034133.</mixed-citation></ref>
<ref id="pone.0191788.ref051"><label>51</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Wright</surname> <given-names>C</given-names></name>, <name name-style="western"><surname>Hynynen</surname> <given-names>K</given-names></name>, <name name-style="western"><surname>Goertz</surname> <given-names>D</given-names></name>. <article-title>In vitro and in vivo high-intensity focused ultrasound thrombolysis</article-title>. <source>Invest Radiol</source>. <year>2012</year>;<volume>47</volume>(<issue>4</issue>):<fpage>217</fpage>–<lpage>25</lpage>. Epub 2012/03/01. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1097/RLI.0b013e31823cc75c" xlink:type="simple">10.1097/RLI.0b013e31823cc75c</ext-link></comment> <object-id pub-id-type="pmid">22373533</object-id>; PubMed Central PMCID: PMCPMC3302946.</mixed-citation></ref>
<ref id="pone.0191788.ref052"><label>52</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Tang</surname> <given-names>SC</given-names></name>, <name name-style="western"><surname>Clement</surname> <given-names>GT</given-names></name>. <article-title>Standing-wave suppression for transcranial ultrasound by random modulation</article-title>. <source>IEEE Trans Biomed Eng</source>. <year>2010</year>;<volume>57</volume>(<issue>1</issue>):<fpage>203</fpage>–<lpage>5</lpage>. Epub 2009/08/22. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1109/TBME.2009.2028653" xlink:type="simple">10.1109/TBME.2009.2028653</ext-link></comment> <object-id pub-id-type="pmid">19695991</object-id>; PubMed Central PMCID: PMCPMC2887681.</mixed-citation></ref>
<ref id="pone.0191788.ref053"><label>53</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Clement</surname> <given-names>GT</given-names></name>, <name name-style="western"><surname>Hynynen</surname> <given-names>K</given-names></name>. <article-title>A non-invasive method for focusing ultrasound through the human skull</article-title>. <source>Phys Med Biol</source>. <year>2002</year>;<volume>47</volume>(<issue>8</issue>):<fpage>1219</fpage>–<lpage>36</lpage>. Epub 2002/05/28. <object-id pub-id-type="pmid">12030552</object-id>.</mixed-citation></ref>
<ref id="pone.0191788.ref054"><label>54</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Ghanouni</surname> <given-names>P</given-names></name>, <name name-style="western"><surname>Pauly</surname> <given-names>KB</given-names></name>, <name name-style="western"><surname>Elias</surname> <given-names>WJ</given-names></name>, <name name-style="western"><surname>Henderson</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Sheehan</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Monteith</surname> <given-names>S</given-names></name>, <etal>et al</etal>. <article-title>Transcranial MRI-Guided Focused Ultrasound: A Review of the Technologic and Neurologic Applications</article-title>. <source>AJR Am J Roentgenol</source>. <year>2015</year>;<volume>205</volume>(<issue>1</issue>):<fpage>150</fpage>–<lpage>9</lpage>. Epub 2015/06/24. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.2214/AJR.14.13632" xlink:type="simple">10.2214/AJR.14.13632</ext-link></comment> <object-id pub-id-type="pmid">26102394</object-id>; PubMed Central PMCID: PMCPMC4687492.</mixed-citation></ref>
<ref id="pone.0191788.ref055"><label>55</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Barreto</surname> <given-names>AD</given-names></name>, <name name-style="western"><surname>Alexandrov</surname> <given-names>AV</given-names></name>, <name name-style="western"><surname>Shen</surname> <given-names>L</given-names></name>, <name name-style="western"><surname>Sisson</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Bursaw</surname> <given-names>AW</given-names></name>, <name name-style="western"><surname>Sahota</surname> <given-names>P</given-names></name>, <etal>et al</etal>. <article-title>CLOTBUST-Hands Free: pilot safety study of a novel operator-independent ultrasound device in patients with acute ischemic stroke</article-title>. <source>Stroke</source>. <year>2013</year>;<volume>44</volume>(<issue>12</issue>):<fpage>3376</fpage>–<lpage>81</lpage>. Epub 2013/10/26. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1161/STROKEAHA.113.002713" xlink:type="simple">10.1161/STROKEAHA.113.002713</ext-link></comment> <object-id pub-id-type="pmid">24159060</object-id>.</mixed-citation></ref>
<ref id="pone.0191788.ref056"><label>56</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>McMahon</surname> <given-names>D</given-names></name>, <name name-style="western"><surname>Hynynen</surname> <given-names>K</given-names></name>. <article-title>Acute Inflammatory Response Following Increased Blood-Brain Barrier Permeability Induced by Focused Ultrasound is Dependent on Microbubble Dose</article-title>. <source>Theranostics</source>. <year>2017</year>;<volume>7</volume>(<issue>16</issue>):<fpage>3989</fpage>–<lpage>4000</lpage>. Epub 2017/11/08. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.7150/thno.21630" xlink:type="simple">10.7150/thno.21630</ext-link></comment> <object-id pub-id-type="pmid">29109793</object-id>; PubMed Central PMCID: PMCPMC5667420.</mixed-citation></ref>
</ref-list>
</back>
</article>